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Abstract  
Healthcare expenditure is on the rise, forming currently 9,5 % of the gross national 
product in Finland. Further rising is anticipated with the ageing population. Medical 
doctors make treatment decisions, and therefore also make an impact on costs. A big 
health, social services and regional government reform is to be initiated in Finland. This 
will put pressure also on medical doctors to pay notice to healthcare costs. 
The purpose of this study was to find out how information on costs of treatment would 
affect Finnish medical doctors’ clinical decision-making. 56 doctors from three public 
healthcare organizations participated in an internet-based study spring 2017. They were 
given a hypothetical patient case along with evidence-based treatment options based on 
Current Care guidelines, and information on costs. Then, they were asked to evaluate 
whether cost information affected their clinical decision-making. They were also 
presented various claims on the relationship between costs and clinical effects, and asked 
about which stakeholders should evaluate this relationship.  
Two out of three medical doctors said that cost information does not affect clinical 
decisions making. In clinical decision-making, emphasis is on the clinical side. Many 
would, however, choose the most cost-effective treatment option, if the options were 
clinically equal. In case cost difference was remarkable, some might choose the cheaper 
but clinically less efficient option. As for stakeholders to evaluate the relationship 
between costs and treatment options, the respondents most often chose the medical doctor 
treating patient, local organizational managers, Ministry of Social Affairs and Health / 
Parliament, the National Advisory Board on Social Welfare and Health Care Ethics 
(ETENE). 
I hope this thesis will offer inspiration for healthcare managers when pondering, how 
medical doctors might be lead towards more cost-reducing practices. In this thesis, also 
costing systems applicable in healthcare were reviewed. Knowledge about these will be 
emphasized during the planned big health and social services reform in Finland. It is good 
also for the medical profession, which has a profound knowledge of the branch, to know 
how costs are formed. I further hope this thesis would serve to stimulate discussion on 
costs in healthcare among medical doctors and, also, on our possibility to affect these 
costs.  
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Tiivistelmä 
Terveydenhuollon kustannukset kasvavat. Niiden osuus bruttokansantuotteestamme 
on 9,5 prosenttia. Kun väestö vanhenee, kustannusten kasvu kiihtyy. Lääkärit tekevät 
hoitopäätöksiä, ja täten vaikuttavat syntyviin kustannuksiin. Suunnitteilla olevan suuren 
sosiaali- ja terveydenhuollon uudistuksen myötä myös lääkärikunnan tulee lisätä 
kustannustietoisuuttaan ja -osaamistaan. 
Tässä tutkimuksessa selvitän, miten tieto hoidon kustannuksista vaikuttaa lääkäreiden 
hoitopäätöksiin. Sähköiseen kyselytutkimukseen osallistui 56 lääkäriä kolmesta julkisen 
terveydenhuollon organisaatiosta keväällä 2017. Heille esitetiin kuvitteellinen 
potilastapaus, Käypä hoito -suositusten mukaiset hoitovaihtoehdot ja niiden 
kustannustiedot. Tämän jälkeen pyydettiin arvioimaan, vaikuttiko kustannustietojen 
esittäminen omaan hoitopäätökseen. Lisäksi kysyttiin mielipiteitä hoitojen 
kustannuksista suhteessa niiden kliiniseen hyötyyn erilaisten väittämien avulla, sekä 
kysyttiin kenen tulisi tehdä päätöksiä siitä, miten hoidon hinta vaikuttaa sen valintaan. 
 Kaksi kolmesta lääkäristä arvioi, ettei tieto hoidon kustannuksista vaikuta 
hoitopäätökseen. Hoitopäätöksissä lääkärit painottivat kliinisiä seikkoja. Monet kuitenkin 
valitsisivat kustannustehokkaimman vaihtoehdon, mikäli hoidot olisivat kliinisesti 
samanarvoisia. Mikäli kustannusero olisi huomattava, saattaisi osa valita myös 
halvemman, mutta kliinisesti tehottomamman hoidon. Tahoiksi, joiden tulisi arvioida 
kustannusten vaikutusta hoitovaihtoehtoihin, vastaajat valitsivat useimmiten hoitavan 
lääkärin tai paikallisen organisaation johdon, sekä STM:n ja valtakunnallinen sosiaali- ja 
terveysalan eettinen neuvottelukunnan (ETENE). 
Toivon tämän tutkielman tarjoavan terveydenhuollon johtajille virikkeitä heidän 
pohtiessaan sitä, miten lääkärikuntaa voitaisiin ohjata kustannustehokkaisiin 
toimintatapoihin. Tässä tutkielmassa on myös esitetty terveydenhuollossa käyttökelpoisia 
kustannuslaskentatapoja. Näiden tuntemus korostunee Suomessa suunnitellun sosiaali- ja 
terveydenhuollon muutoksen myötä. Tällöin myös lääkärikunnan, jolla on vahva 
toimialatuntemus, on hyvä tuntea kustannusten muodostumista. Toivon, että tämä 
tutkimus myös stimuloi lääkärikunnan keskustelua terveydenhuollon kustannuksista ja 
ammattikuntamme mahdollisuudesta vaikuttaa niihin.  
 
Avainsanat   terveydenhuolto, kustannus, lääkäri, päätöksenteko   
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1. Introduction 
 
1.1. Background 
Health expenditure and financing has grown steadily in the majority or the OECD 
countries during the present millennium (OECD 2017). In the US, health care costs 
already exceed 17 % of GDP in year 2011 (Kaplan and Porter, 2011). In Finland in 2014, 
health care costs were 19,5 billion euros, making 3 576 euros per capita and forming 9,5 
% of the gross national product (Matveinen and Knape, 2016). 
An ageing population and continuous development of treatment methods are major 
factors behind the rising health care costs in the western countries. In Finland, the 
proportion of residents aged 65 years and older was 21 % in 2016. Statistics Finland has 
projected that by year 2030 this age group will already form 26 % of the population 
(Official Statistics of Finland, 2012). In absolute numbers, this equals approximately 
1 150 000 elderly residents in 2016 and approximately 1 722 000 in 2030. As shown by 
a recent report on the Finnish population by the National Institute for Health and Welfare, 
health care expenditure per capita rises by increasing age (Kaipainen and Eskelinen, 
2014). 
Once a person contacts healthcare, the healthcare personnel decides on the choice of 
diagnostic investigations, treatments, as well as rehabilitation interventions. In our 
Finnish healthcare system, these tasks are mainly assigned to medical doctors, even 
though some other professions such as therapists (eg. physiotherapists, psychotherapists), 
nurses and psychologists participate in these actions to some extent. Therefore, most 
health care costs derive from decisions made my medical doctors. This is what is meant 
by the saying that ‘the doctor’s pen is the most expensive instrument in health care’. 
Health care aims at prevention, cure and rehabilitation of illness as well as maintenance 
of health. This is the first and foremost reason of all medical treatment. Medical doctors 
might not consider costs at all at the point of clinical decision-making. On the moment a 
medical doctor makes a decision on diagnostic tests or treatment or rehabilitation 
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interventions, the moment the doctor also makes a decision on use and allocation of costs, 
whether he or she thinks about it or likes it or not. This has also been a topic of discussion. 
For example, I have heard pondering on whether healthcare costs could be reduced in 
case doctors would take costs into account every time they make a clinical decision. A 
more radical thought is whether doctors should be ‘forced’ to consider costs and, also, to 
use the most cost-effective option. Doctors have also wondered whether considering costs 
is a doctor’s job in the first place. Further, another interesting topic is whom or which 
profession or stakeholder should be the one weighing the burden of costs against clinical 
benefits of treatments. Stakeholders such as the medical profession, managers, and 
politicians have been mentioned in these discussions. Whichever the answers would be 
and in whose opinion, the topic of limited healthcare resources and a pressure for cost 
control is a current issue that we cannot escape. 
As medical doctors play a key role in the chain of producing both value to the patient and 
healthcare costs to the society, let me continue by enlightening the line of thought a 
medical doctor typically follows. Describing this ages-old profession, this cannot be done 
without referring to the Hippocratic Oath, which I will cite in the following chapter. I will 
then highlight what is presently known about medical doctors’ awareness on costs, 
identify the research gap leading to this study, define the research questions, and introduce 
the reader the structure of this thesis. 
 
1.2. The medical doctors’ mindset and the Hippocratic Oath 
 
Primium est non nocere (latin). This, possibly the most famous of Hippocrates’ thoughts 
on patient care, advices a doctor not to harm his patient. Another well-known thought of 
his advices to detain from doing harm even in the case when you cannot cure or help. 
The legacy of Hippocrates lives on. The Hippocratic Oath, an oath obligating us to act to 
the best of our patients, is taken across countries by medical students upon graduation 
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(U.S. National Library of Medicine, 2017). Upon reading the Hippocratic Oath it is easy 
to understand that medical doctors, practitioners of this ages-old profession, are oriented 
in clinical rather than not economic thinking. The Hippocratic Oath has undergone 
various modernization phases. A version modernized in 1964 (Lasagna, 1964) is given 
below. The English translation of the original version (Edelstein, 1943) is given in 
Appendix 1. In Finland, The Finnish Medical Association (FMA) has modified a Finnsh 
version of the oath, called the ‘Medical Doctor’s Oath’ (Lääkäriliitto, 2017), which is 
given in Appendix 2. It is taken by most Finnish medical students upon graduation 
(Kattelus, 2017). 
Hippocratic Oath 
I swear to fulfill, to the best of my ability and judgment, this 
covenant: 
I will respect the hard-won scientific gains of those physicians 
in whose steps I walk, and gladly share such knowledge as is 
mine with those who are to follow. 
I will apply, for the benefit of the sick, all measures [that] are 
required, avoiding those twin traps of overtreatment and 
therapeutic nihilism. 
I will remember that there is art to medicine as well as science, 
and that warmth, sympathy, and understanding may outweigh 
the surgeon's knife or the chemist's drug. 
I will not be ashamed to say "I know not," nor will I fail to call 
in my colleagues when the skills of another are needed for a 
patient's recovery. 
I will respect the privacy of my patients, for their problems 
are not disclosed to me that the world may know. Most 
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especially must I tread with care in matters of life and death. 
If it is given me to save a life, all thanks. But it may also be 
within my power to take a life; this awesome responsibility 
must be faced with great humbleness and awareness of my 
own frailty. Above all, I must not play at God. 
I will remember that I do not treat a fever chart, a cancerous 
growth, but a sick human being, whose illness may affect the 
person's family and economic stability. My responsibility 
includes these related problems, if I am to care adequately for 
the sick. 
I will prevent disease whenever I can, for prevention is 
preferable to cure. 
I will remember that I remain a member of society, with 
special obligations to all my fellow human beings, those 
sound of mind and body as well as the infirm. 
If I do not violate this oath, may I enjoy life and art, respected 
while I live and remembered with affection thereafter. May I 
always act so as to preserve the finest traditions of my calling 
and may I long experience the joy of healing those who seek 
my help. 
 
Would thinking about costs violate the Hippocratic Oath? Emeritus professor Markku 
Järvinen reminds that each medical oath reflects its own era (Järvinen, 2016) and emeritus 
professor Martti Kekomäki points out how Hippocrates lived in a totally different 
environment than we do: “Hippocrates did not live under a health care budget set by the 
city of Athens” (Kekomäki, 2016). Indeed, Hippocrates did live some two thousand years 
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before our relatively new era of health economics and, as Kaplan and Porter put it, the 
“cost crisis in health care” (Kaplan and Porter, 2011). 
 
1.3. The medical doctors’ awareness of costs 
The way medical doctors see themselves as personnel having to take economical aspects 
into account seems to vary. According to a survey by Tilburt et al. (2013) among 2 556 
randomly selected American medical doctors only 36 % reported that they have “major 
responsibility” for reducing health care costs. They also named other parties like patients, 
hospitals and health systems, pharmaceutical and device manufacturers, trial lawyers and 
health insurance companies, to be responsible (Tilburt, 2013). However, another study 
reports views of medical doctors who consider that the medical profession specifically 
should be involved in cost considerations (Brook, 2014).  
Irrespective of whether medical doctors themselves think that they should or should not 
be active players in cost reductions there has, due to their central role, been interest to 
find out how aware of costs medical doctors are in the first place. It seems that medical 
doctors do not seem to be very aware of the true costs of either diagnostic tests (Allan and 
Lexchin, 2008; Vijayasarathi et al., 2016), treatments (Allan and Lexchin, 2008) or 
rehabilitation interventions (Kuiken, Prather and Bloom, 1996), as shown by the 
following studies. 
Allan and Lexchin (2008) performed a systematic literature review in order to see how 
aware medical doctors are on the costs of diagnostic tests or treatments other than 
medicines. They found only fourteen articles that were eligible for their final analysis. 
Based on these, they found out that doctors are very inaccurate in their estimations on 
costs. The poor accuracy was not dependent on demographic features such as country, 
year of study, level of training or field of specialization. 
Vijayasarathi et al. (2016) conducted an online survey on more than 1 200 medical doctors 
in the US in order to find out how well they were aware of the costs of computerized 
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tomography (CT). CT is a radiologic imaging technique used largely in diagnostics, but 
also on follow-up of some diseases. The machinery is expensive. Vijayasarathi et al. 
(2016) found out that that the doctors’ knowledge on the costs was poor. Each respondent 
was asked to evaluate the cost of five different, commonly used CT scans. Only 
approximately 6 % of the evaluations fell even in the range of ±25 % of the correct cost, 
the other evaluations being even more incorrect. Those working in the radiology 
department, whose area of expertise the CT scans are, did not do any better than those 
working in other departments. 
Kuiken, Prather and Bloom (1996) studied medical doctors’ awareness on the costs of 
rehabilitation. Forty-six American medical doctors were asked about various individual 
interventions in the rehabilitation process. Their estimation on costs were hugely 
inaccurate. For example, they made on average approximately 50 % errors when 
estimating costs of blood sample analyses or imaging techniques, and even 100 % errors 
when estimating costs of pharmaceuticals. In their study, the doctors were also asked on 
how confident they felt with their own estimations. They answered not being confident at 
all: they described their estimations were pure guesses in 80 to 90 % of their estimates 
(Kuiken, Prather and Bloom, 1996). Alike in the studies by Allan and Lexchin (2008) and 
Vijayasarathi et al. (2016), also in this study by Kuiken, Prather and Bloom (1996) the 
level of experience of the doctor was not associated with the accuracy of knowing costs. 
Both Allan and Lexchin (2008) and Vijayasarathi et al. (2016) conclude that doctors’ 
awareness on costs should be raised. This might be achieved by bringing cost data 
available to doctors in the clinical situations. Long et al. (2016) designed an intervention 
study to see whether doctors’ awareness on the costs of blood sample analyses could be 
raised by providing visual display of costs of each analysis the doctors intend to order. 
They found out that via this means the awareness was indeed raised (Long et al., 2016). 
What remains to be seen is whether such awareness would affect decision-making, and 
result in choosing less costly choices and thereby in cost reductions. 
 
 12 
 
1.4. Research gap, research questions and contribution of the study 
The need for this study arises from the following two empiric notions. First, doctors make 
clinical treatment decisions that define both instant costs and costs occurring in the future. 
Second, there is, to my knowledge, no evaluation done on the attitudes of Finnish doctors 
towards having to consider costs at the time of clinical treatment decisions. Neither am I 
aware of a similar international study, though I cannot rule out the possibility that one 
exists. The aim of this study is to find out how information on costs of treatment would 
affect Finnish medical doctors’ clinical decision-making. As, at present, we lack this 
information, the present study was designed to fill this research gap. 
The specific research questions are as follows.  
- Does information on the costs of treatment affect clinical decision-making of 
Finnish medical doctors, as evaluated by themselves? 
- What are the reasons that the information on costs does or does not affect clinical 
decision-making? 
- Who should decide on how costs of treatment should affect treatment choices, as 
evaluated by the doctors? 
This study will serve several purposes. First, it will contribute to the literature in the field. 
Secondly, the observations made in this study can have direct practical implications. It 
gives grounds to considering whether leading medical doctors by cost information would 
result in cost reductions. In such a case, a practical implication for software vendors 
would be to add information on costs in the electronic tools used by doctors. Thirdly, I 
hope this study adds to the ongoing larger discussion on whose role it is to make decisions 
on costs of health care and at which level should these decisions be made: at the everyday 
doctor-patient interaction, at healthcare organizations’ managerial level, or at societal 
level. The latter would include, for example, decisions on what treatments are to be 
offered by public health care. The theme is highly contemporary. 
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1.5. Structure of the thesis 
Following the introductory part this Master’s thesis is structured into five main parts. 
First, a literature review is given in Part 2. It provides an overview on how outcome is 
measured within healthcare (Chapter 2.1.). It then proceeds into introducing costing 
systems that either acknowledge (Chapter 2.2.) or don’t acknowledge clinical outcomes 
(Chapter 2.3.), and provides an example of combining them (Chapter 2.4.). It also 
introduces the theoretical approach of this study, action research (Chapter 2.5.), and gives 
examples of its use in health care (Chapter 2.5.1.), as well as positions the present study 
within the action research approach (Chapter 2.5.2.). Then, the Methods part describes 
composing the study and introduces the participating organizations (Chapter 3.1.), 
describes composing the cases (Chapter 3.2.), describes performing the study and gives 
the response rates (Chapter 3.3.), and discusses ethical aspects (Chapter 3.4.). In the next 
part, empirical findings are presented along with their analysis and discussion (Part 4). 
Here, the findings are grouped into the following themes or entities: response rates 
(Chapter 4.1.), the degree to which information on costs affected decision-making 
(Chapter 4.2.), attitudes on bringing out information on costs at the point of clinical 
decision-making (Chapter 4.3.), the doctor’s time (Chapter 4.3.), treatment decisions 
being based on clinical aspects (Chapter 4.5.), the patient and citizen as a paying party 
(Chapter 4.6.), the society as a paying party (Chapter 4.7.), ethicality  (Chapter 4.8.), 
stakeholders to evaluate how information on costs should affect clinical decision-making 
(Chapter 4.9.), and medical doctors and costing systems (Chapter 4.10.). Following this, 
a summary of the findings is given (Chapter 4.11.). Finally, a conclusion of the study is 
made by providing a research summary (Chapter 5.1.), practical implications (Chapter 
5.2.), limitations of the study (Chapter 5.3.) and suggestions for further research (Chapter 
5.4.).  
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2. Literature review 
This literature review introduces the methods of evaluating costs in health care. The 
uniqueness of health care as an industry lies in the outcome, health. As health is so 
precious to us and, righteously so, seen as a human right, the costs of individual 
treatments, treatment processes or health systems in general should not be addressed 
without paying notice to the health outcomes. Therefore, in this chapter I will first offer 
an introduction to how health outcomes may be assessed.  
The costing methods introduced in this chapter may be categorized in two: those methods 
that combine costs with clinical health outcomes and those that do not, but have costs and 
resource use as the only viewpoints. The first have been developed within healthcare and 
fall in the academic field of health economics. The latter originate from other industries 
and have only recently been implemented in health care. 
The two major methods used for cost assessing in health economics are the cost-
effectiveness analysis and cost-utility analysis. In cost-effectiveness analysis costs of a 
treatment are evaluated in relation to clinical outcomes, e.g. a decrease in blood pressure 
or improvement of asthma symptoms. Cost-utility analysis takes it further: costs are 
analyzed in relation not only to an individual clinical outcome, but to the health-related 
quality of life. This allows calculating the so-called quality-adjusted life years (QALY) 
gained. Following this, a brief word is given to key performance indicators and the 
Choosing Wisely initiative, that aims ridding healthcare from waste caused by 
unnecessary treatments.   
In other industries cost analyses seem to have a stronger tradition than in health care, at 
least in the public healthcare in Finland. This is natural, as any for-profit business needs 
to continuously make efforts in cutting down costs and maximizing profit. Among the 
medical profession there tends to be discussion on whether such methods for assessing 
costs, that are used in other industries, can or cannot be implemented into medicine. 
Usually the conclusion is that they cannot. The argument typically lies in the uniqueness 
of health care, the line of thought being: ‘as health and longevity of life may not be 
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evaluated in monetary units, pure costing assessment is not applicable to health care’. In 
this literature review I will introduce the reader to two costing systems that originate from 
other industries and that have been successfully used in healthcare, namely the activity-
based costing system (ABC) and the time-driven activity-based costing system 
(TDABC). For comparison, the traditional costing system of hospitals is briefly 
introduced. I will also show how the industry-driven TDABC may be successfully 
combined with the ‘clinical’ cost-utility assessment. 
This study falls within the theoretical approach of action research, which is introduced. 
Due to its versatility, it has also been used in various kinds of studies within healthcare, 
examples of which are given. I will also describe how the present study falls within the 
action research approach. Finally, a summary of the literature review will be given.  
 
2.1. Assessing clinical outcome and performance 
 
2.1.1. Clinical outcome measures 
 
Clinical outcomes are various. They may be classified into those reported by healthcare 
professionals and those reported by patients (patient-reported outcomes, PRO), and may 
be collected into registers. Outcomes reported by professionals typically address 
parameters objectively assessible, such as disease status or mortality. Those reported by 
patients typically address parameters related to functionality and well-being, such as pain 
or quality of life. As an example, one’s knee joint might be assessed by a professional, 
e.g. a physiotherapist measuring the angle of flexion, and by the patient reporting whether 
it is possible to play football. The U.S. Food and Drug administration (2017) (REF) 
provides the following definition for PRO: “A PRO is a measurement based on a report 
that comes directly from the patient (i.e., study subject) about the status of a patient’s 
health condition without amendment or interpretation of the patient’s report by a clinician 
or anyone else.” PRO measurement is usually conducted via a questionnaire: patient 
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reported outcome measure (PROM). For example, the EQ5D is a 5-item questionnaire 
used for measuring a person’s quality of life.   
Another term and aspect is patient-reported experience measures (PREM), which 
measure satisfaction or experience with the care process. Concerning the nomenclature, 
it has also been suggested that PROM could stand for person-reported outcome measures, 
as not all subjects reporting health outcomes are patients (Fayers and Machin, 2007).  
PROs may be used, as Van der Wees et al. (2014) describe, for purposes such as 
practice improvement, assessment of the performance of clinicians and organizations, 
and as a metric for value-based payments. Nilsson et al. (2015) describe earlier research 
data showing how collecting PROs may improve patient–provider communication and 
patient satisfaction. Further, there are promising views on aggregated data at 
organizational, regional or national level helping evaluate healthcare performance by, 
for example, benchmarking. In Sweden, national quality registers are advanced. As 
Nilsson et al. (2015) describe, in the Swedish healthcare system national quality 
registers are obliged to incorporate PROs. These are used for example to improve the 
precision for indications of surgery or to improve patient information. Clinical 
outcomes may be incorporated in economic evaluation in the cost-effectiveness or cost-
utility analysis, as described later (see chapter 2.2.). 
 
2.1.2. Health-related quality of life (HRQoL) and Quality-adjusted life years 
(QALY) 
Taking defining health outcome further, to a more holistic level, and also in order to better 
estimate the impact of treatments on a person’s well-being, several assessment scales for 
evaluating health-related quality of life (HRQoL) have been developed. Some are 
categorized as generic and may be used with any health intervention, as they measure 
HRQoL in general. One such scale is the 15D-scale, which has been developed by 
Sintonen and his colleagues in Finland (Sintonen, 2001). These enable comparison of the 
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benefits of treatments across medical specialties. In addition to these generic scales there 
are disease-specific scales designed for use with individual illnesses only (Mittal 2006). 
In addition to quality of life we people value its longevity.  Once change in HRQoL, 
achieved by a healthcare intervention, is combined with the change in longevity (life 
expectancy) quality-adjusted life years (QALY) will be gained. Alike the more direct 
clinical outcome measures described earlier, QALYs may be incorporated in economic 
evaluation, namely in cost-utility analysis (see chapter 2.2.2.).  
 
2.1.3. Key Performance indicators and Choosing Wisely 
 
Quality of performance in health care has been monitored by performance indicators. In 
addition to being used as a means to both measure and improve quality, they have also 
been used for to achieving and proving equality of treatment between units. These quality 
indicators may be process or outcome indicators. They may also be used as managerial 
vehicles for improving performance between units, as productivity per unit may be 
analyzed. (Peled, 2016)  
One form of poor productivity is activity that does not produce any good at all. Within 
healthcare, this would mean treatments that are not effective. In addition to being a 
productivity loss such treatments may also be characterized unethical: they subject a 
person to possible side-effects while no beneficial effects are achieved, and give a person 
groundless hope of being cured. The Choosing Wisely -campaign by the American Board 
of Internal Medicine has addressed this issue with the goal being “to reduce waste in the 
health care system and avoid risks associated with unnecessary treatment” (ABIM 
Foundation, 2017). The need for this initiative has been seen, and the initiative been 
adopted, in many countries. Further national initiatives include, among others, Choosing 
Wisely UK (2017), Choosing Wisely Canada (2017), and Choosing Wisely Australia 
(2016). In Finland, the Finnish Medical Society Duodecim has, in 2016, initiated a similar 
practice (Käypä hoito, 2017). The aim is to improve effectivity, productivity and safety 
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of health care by letting go such old treatment options that are not based on scientific 
evidence.  
 
2.2. Cost assessment in healthcare, acknowledging clinical outcome 
 
2.2.1. Cost-effectiveness analysis 
 
Costs of particular treatments comprise direct and indirect (productivity) costs. 
Evaluating the former is easier, as it comprises tangible within-treatment-producer costs 
such as equipment and personnel costs. The latter comprises, for example, travel costs 
and costs due to absence of work and are, therefore, more indirect and hence more 
difficult to estimate (Drummond 2005). Time-driven activity-based costing increases the 
accuracy of analyzing treatment costs. Time-driven activity-based costing further allows 
estimating the costs per patient per individual treatment episodes (Kaplan and Anderson 
2004; Kaplan and Porter, 2011).  
 
2.2.2. Cost-utility analysis 
 
Cost-utility analysis refers to the ratio of costs to QALYs. It is considered as the preferred 
method of economic evaluation in healthcare, as it notifies the impact of the healthcare 
intervention on HRQoL. Cost-utility is expressed as a monetary unit per QALY gained. 
The question that prevails without precise answers is, how much can one QALY gained 
cost? In Finland, no accepted cost per QALY has been defined. Internationally, an 
accepted cost of a QALY would surely depend on the gross national product as well as 
cultural features on how different health outcomes and illnesses are valued. In the United 
Kingdom, the National Institute for Health and Clinical Excellence (NICE) has outlined, 
that interventions costing less than £20 000 may be regarded cost-effective enough to be 
provided by the public sector. Interventions costing between £20 000 and £30 000 should 
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be evaluated against how precise and solid the estimations of health benefits gained by 
them are. This evaluation is emphasized once considering interventions that would cost 
more than £30 000 per QALY. (National Institute for Health and Clinical Excellence, 
2017) 
 
2.3. Cost assessment in healthcare, not acknowledging clinical outcome 
 
2.3.1. Traditional costing system 
 
Öker and Özyapici (2013), in their comparison of different costing systems, describe the 
traditional costing system that has been widely used. Here patient-days are used as the 
cost driver. First, direct costs, such as doctor and nurse costs and medicine costs, are 
allocated to the appropriate services. All other costs are allocated by patient-days. This 
leads to inaccurate costing estimates. As one example Öker and Özyapici (2013) give 
customer service representatives’ work upon discharging patients from hospital. Each 
patient discharge requires a similar and therefore equally time-consuming service from 
them. Yet, as patient-days are the cost driver, a patient who has stayed in hospital for five 
days is allocated five times more for this service than a fellow patient who stayed for only 
one day. This leads to overestimation of costs of such treatments that require a longer in-
hospital stay and underestimation of costs of such treatments that only require a shorter 
in-hospital stay. 
 
2.3.2. Activity-based costing system (ABC) 
 
The activity-based costing system (ABC) was regarded as a welcome improvement in 
costing and it solved the basic problem of the traditional costing system described above. 
It does not consider patient-days as the driver for costs as in the traditional costing system 
but, as its name implies, the activities undertaken. In ABC, a two-stage activity is 
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performed: costs are first assigned to activities and following this to products and services 
(Hansen, 2006). However, as one disadvantage, ABC was found not to notice unused 
capacity (Öker 2013).  
 
2.3.3. Time-driven activity-based costing system (TDABC) 
 
Time-driven activity-based costing system (TDABC) was introduced by Kaplan and 
Anderson in 2004. It builds on ABC by adding the element of time and keeping it the 
cost-driver. In short, the following steps are taken in TDABC. First, the cost per time unit 
is estimated. This may be done by dividing the cost of the resource, for example a person’s 
monthly salary, with the amount of minutes the person works a month. Here, it is assumed 
that some 20 % of working time is spent on activities other than work itself. This includes, 
for example, breaks, communication and training. Therefore, dividing the salary with this 
practical working time, i.e. 80 % of the full working time, gives the cost per unit. (Kaplan 
& Anderson 2004) 
The second step in performing TDABC is to estimate the unit times of activities. A unit 
time means the number of minutes it takes to perform one task. (Kaplan & Anderson 
2014) In healthcare, this could, for example, be the number of minutes it takes to perform 
an electrocardiogram recording (ECG). This may be done by interviewing employees or 
by direct observation (Kaplan & Anderson 2014). The third step is deriving cost-driver 
rates. This happens by multiplying the cost per time unit and the unit time just described. 
(Kaplan & Anderson 2014) Let me give an example. 
Let us assume that it takes five minutes to perform the ECG by a nurse. The nurse’s 
monthly salary in Finland might be 2 400 € (SuPer, 2017), and total expenses to employer 
3 600 € (includes social security expenses and bonus holiday pays). Full theoretical 
working time might be 38 hours 15 minutes a week (Palkkavertailu, 2017), equaling 
approximately 9 639 minutes a month. With these assumptions, the cost per unit would 
be as follows: 3 600 € / (0,8 x 9639 min) = 0,47 €/min. As we assumed five minutes to 
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be the unit time of activity, we will get the following cost-driver rate for a nurse 
performing an ECG: 5 min x 0,47 €/min = 2,35 €. 
The advantage of this approach, as compared to the traditional ABC, is seen to be superior 
accuracy in estimating the cost of an activity. Further, TDABC is described to be flexible 
and easy-to-use in case changes would occur in any of the parameters included in the 
calculation (salaries, time spent). Further, it has been found useful in identifying where 
there is waste or suboptimal use of human resources. All these features are beneficial in 
process planning, cost control and resource allocation (Kaplan & Anderson 2004; Kaplan 
et al. 2014; Öker and Özyapici 2013). 
Despite the novelty of TDABC in healthcare, examples of its successful use are already 
a few from different branches of medicine. These include acute and non-acute fields, such 
as the emergency room and out-patient treatment of depression, respectively, and 
operative and non-operative units, such an orthopedic unit and a cancer center, 
respectively (Alaoui and Lindefors 2016; Kaplan et al. 2014; Yun et al. 2016). TDABC 
has been shown to help in identifying various kinds of slack. For example, the Boston 
Children’s Hospital orthopedic department identified how a single activity, a slight 
disturbances in processing X-ray orders, resulted in unexpectedly high additional costs as 
well as prolonged waiting times for patients. The Brigham Women’s Hospital orthopedic 
department, on the other hand, observed that through the entirety of their care cycle, from 
admission to post-operative follow-up visits, several steps could be improved and used 
together to improve the entirety. (Kaplan et al. 2014) In the emergency room setting, 
TDABC seems to offer an excellent tool for process improvements (Yun et al. 2016). In 
addition to these examples from high-income countries, Mandigo et al. (2015) performed 
a pilot study in Haiti, one of the poorest countries in the world. An example of improving 
their processes upon using TDABC was streamlining sterilization procedures of 
instruments. The importance of cost savings becomes emphasized in low-income settings.  
Kaplan et al. (2014) also identified what it takes to make TDABC work as well as it did 
in the above examples. The crucial points are that the organization needs to provide time 
for implementing TDABC, medical managers and their teams need to engage in 
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identifying the process of patient care, and financial managers need to be co-operative in 
providing costs to each activity of the patient care process identified by the medical team. 
If any part of this managemental trio fails to co-operate, no results will be gained. 
The novelty of TDABC in the healthcare sector also raises, righteously so, cautious 
voices. Although TDABC is, by many, considered superior to the so far used costing 
systems within healthcare, Sharon et al. (2016) make the following point.  
“Although TDABC is being advocated by important opinion leaders in the 
field of health care economics, it is worth pointing out that independent 
researchers are only now beginning to explore the usefulness of this 
technique in clinical practice.” 
Sharon et al. (2016) continue to explain their thought by saying that techniques that might 
work in the hands of experts might be difficult to employ by non-experts. Further, they 
consider that once becoming wider used this costing technique might further evolve in 
the hands of its users. 
 
2.4. Combining TDABC and clinical cost-effectiveness 
 
Alaoui and Lindefors (2016) have performed a study where they combined TDABC and 
clinical outcomes in cost-effectiveness analysis. The study setting was a public hospital 
in Sweden. The disease analyzed was depression due to its major burden on health: 
depression has been identified as the second-leading cause of disability worldwide in the 
Global Burden of Disease study (Alaoui and Lindefors 2016; Ferrari 2013). The treatment 
method analyzed was internet-based psychotherapy, as it has both been shown to be 
effective and, also, offers as an innovative solution to reduce the queues for treatment. In 
the first phase of their study, Alaoui and Lindefors (2016) used TDABC to identify actual 
costs and use of time of personnel more precisely as earlier. Following this, cost-
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effectiveness analysis, which combined clinical outcomes (alleviation of depression in 
Patient Health Questionnaire depression scale PHQ-9) with the costs of treatment gained 
in the first phase by TDABC, was performed. The study showed that the psychiatric unit 
could improve their use of human resources and reduce costs with no compromise in 
clinical outcomes. Namely, doctors, of whose time there was lack of, could be replaced 
with psychologists for a particularly identified activity in the treatment process (post-
treatment assessment). Costs per treated case reduced from $709 to $659 (international 
dollars1). (Alaoui and Lindefors, 2016) 
This study by Alaoui and Lindefors (2016) is an excellent example of implementing 
TDABC in healthcare and showing that it neither results in any compromises in patient 
care nor causes dissatisfaction in clinicians engaged in the treatment process. Hence, once 
future studies alike this become available, the suspicious minds towards using industry-
derived costing systems in health care may become fewer in number. 
 
2.5. Action research as a research approach  
 
Action research aims at understanding work practices and at improving them. This 
includes acquiring knowledge, identifying influential factors, and by these means 
improving the work practices in focus. In action research, participants are strongly 
involved (McNiff and Whitehead, 2002; McNiff and Whitehead, 2010). Winter and 
Munn-Giddings (2005) describe action research to “bridge the ever-present gap between 
‘theory’ and practice” (pp. 7). The nature of action research comes forward in the quote 
from Swantz (2011): “It is crucial that research is not separated from life.” Depending on 
the perspective of the researcher, action research has, for example, been described to 
                                                 
1  “An international dollar has the same purchasing power as the U.S. dollar has in the United 
States. Costs in local currency units are converted to international dollars using purchasing 
power parity (ppp) exchange rates.” CHOosing Interventions that are Cost Effective (WHO-
CHOICE) by WHO, http://www.who.int/choice/costs/ppp/en/  (cited 9.3.2017). 
 24 
 
interconnect social, biological and ecological sciences as well as to have religious or 
spiritual anchors (Wikcs, Reason and Bradbury, 2011). In more common terms, the 
orientation of action research has been described as ‘practical know-how’ or ‘popular 
science of and for the people’ (Wicks, Reason, and Bradbury, 2011, p. 11).  
Key elements of action research, as identified by McNiff and Whitehead (2002), include 
a) the researcher being central to the process, b) the researcher also learning about one’s 
self, c) the aim being at continuing development rather than closing conclusions, and d) 
the process being participative and educational (p. 203). It is easy to see that action 
research can be applied in any areas of working life and that it is not restricted to any 
discipline. Action research has, indeed, been used in many different contexts (McNiff and 
Whitehead, 2002; McNiff and Whitehead, 2010; Winter and Munn-Giddings, 2005; 
Wikcs, Reason and Bradbury, 2011). 
Within organizational action research the focus can be on improving work practices of 
individuals, but also on managerial aspects or on organizational change (McNiff and 
Whitehead 2002; Bradbury et al., 2011). McNiff and Whitehead (2002) identify three 
paradigms within organizational action research: the interpretative, the critical theoretic, 
and the living theory paradigms. The interpretative approach involves field tutors or 
coaches who support and interpret the work of the field researchers. In the critical 
theoretic approach participants are encouraged to see what factors dominate and control 
their work practices. The living theory approach, on its behalf, encourages individuals to 
identify their values, to try to commit to them in every day work, to observe possible 
contradictions between these values and work practice and, further yet, to try to solve 
these contradictions. These approaches have all been adopted worldwide. (p. 201) 
(McNiff and Whitehead, 2002) 
 
2.5.1. Action research in health care 
Due to its versatility action research has been used for various kinds of research aims also 
within health care (Bate, 2000; Bradbury and Lifvergren, 2016; Hughes, 2011). 
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Waterman et al. (2001, cited by Hughes, 2011) has analyzed the scope of these aims in 
48 British research reports and has shown that “The most common reasons for choosing 
action research are about encouraging stakeholders to participate in making decisions 
about all stages of research, or empowering and supporting participants.” Action research 
has also often been used for the reason that it educates. Further aims in healthcare include 
solving practical, concrete or material problems, or analyzing change (Waterman et al. 
2001, cited by Hughes, 2011). 
In health care, problems might sometimes be multifaceted or involve many stakeholders. 
This may apply at the individual level, i.e. in situations of treating patients, as well as at 
the managerial level. These characteristics are another element that make action research 
applicable for healthcare, as both Bradbury and Lifvergren (2016) and Waterman et al. 
(2001, cited by Hughes, 2011) have shown it to be useful when problems are complex or 
when patients have complex care needs. Bradbury and Lifvergren (2016) argue, based on 
ten years of experience from Sweden, how using the action research approach and 
engaging all stakeholders involved in the various actions of treatment protocols makes it 
possible to achieve two important goals: a) health outcomes are improved and b) costs 
are saved. Another example of involving many stakeholders includes the work by Chiu 
(2011). The author demonstrates the use of participatory action research in the context of 
various community-based programs. In these, various ethnic or language groups were 
involved and the needs of all these separate groups had to be addressed (Chiu, 2011). 
Taken these together, in the work by Bradbury and Lifvergren (2016) the focus was on 
implementing the interventions on the individual level (choosing treatment protocols for 
individual patients) and in the work by Chiu (2011) the focus was on community level. 
Winter and Munn-Giddings (2005) list further examples where action research has been 
used in health care. These include projects involving service-user research, community 
development, management in organizations, as well as reflection on professionals’ own 
work (Winter and Munn-Giddings, 2005).  
Hughes (2011) describes how, in healthcare research, the participatory worldview 
underlying action research is in close connection with the positivist paradigm underlying 
experimental research (p. 3). Here, it is pertinent to notify the typical quantitative research 
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types within healthcare and medical research, and to consider their connection with 
qualitative research, namely, action research. The typical quantitative study types are 
intervention, observational and diagnostic studies and systematic reviews with meta-
analysis, when applicable (Ruffano et al., 2012; Furlan et al. 2009; Schulz, Altman and 
Moher, 2010; Straus et al. 2010; Vandenbroucke, 2004). Intervention studies, and 
especially the randomized controlled trials, are the cornerstone in studying the effects of 
treatments or other interventions (Schulz, Altman and Moher, 2010). Observational 
studies may be used when, for instance, it is not ethical to randomize persons into 
intervention groups (Vandenbroucke, 2004). A classic example is studying the effect of 
tobacco smoke on health. Diagnostic studies, as their name implies, evaluate whether use 
of diagnostic tests result in improved health outcomes (di Ruffano, 2012). Systematic 
reviews and meta-analysis, in their part, may be used to draw together results of any of 
these study types. A meta-analysis may be used to further combine quantitative data in a 
mathematical way. However, systematic reviews may also be used to collect and analyze 
qualitative data (Furlan 2009; Straus, 2010).  
Using systematic reviews on either quantitative or qualitative research as a basis of 
identifying further research needs, for instance for action research settings, is one point 
of connection between these study types. The resent work by Poels et al (2016) offers an 
example of this. Their systematic review is from the field of reproductive health. The aim 
was to find out why women in western countries do not use preconception care once 
planning pregnancy, even though this has been shown to improve pregnancy outcome. 
They identified both barriers and facilitators. Based on their findings they say that it is 
now possible to “refocus interventions and strategies, aiming on enlarging the awareness, 
perceived importance, and accessibility of preconception care to improve its uptake” 
(Poels et al., 2016). Here, I see them raising a typical need for action research, which is: 
‘aiming on enlarging the awareness’. Also, such further research would require 
participation of the women involved which, meaning the participation, again is a call for 
action research, as described earlier (McNiff and Whitehead, 2002; McNiff and 
Whitehead, 2010). 
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In addition to using systematic reviews as a basis for further studies with an action 
research approach, I also see also a way of combining quantitative medical research and 
action research within the same study. Let us continue with the above example. The 
research aim raised by Poels et al. (2016), raising awareness, could be reached by action 
research. However, to find out whether one practice is more efficient than another, a 
comparative study design is needed (Schultz 2010). The way to combine these two aims 
would be to design a study where two or more study populations would be randomly 
allocated to different awareness-raising interventions or to no intervention at all. The 
study populations could be, for example, groups of women, communities, or professionals 
at health care centers. The intervention itself could be carried out as an action research 
project. In this way, the study design would fulfill the criteria of a randomized controlled 
trial (Schultz 2010) and the intervention, aiming to raise awareness could, in turn, be 
carried with the methods of participatory action research (Alber, 2011; Winter and Munn-
Giddings, 2005). 
 
2.5.2. Action research and the present study 
 
In this chapter, I will first summarize the features of the present study. Following this, I 
will explain how the present study fits into the approach of action research. In the end, I 
will evaluate my own position in this study. 
In the present study, the participating Finnish medical doctors, working in the public 
sector, evaluated their own decision-making. Traditionally, in a medical doctor’s 
working day, treatment decisions have been based on clinical information. This 
information includes benefits and harms (effects and side-effects) of treatment and the 
effort a patient must make for the treatment (e.g. repeated laboratory visits). Now, in the 
present study, participants were asked to evaluate their decision-making once new data, 
data on costs, is visible in parallel with the traditional clinical data. This was done by 
first involving the participants in a patient case. The case was hypothetical, but still a 
typical one. Real patient cases were not involved due to reasons of privacy protection. 
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Following this initial stage, the participants were also asked to express their opinions by 
evaluating various claims about the relationship between costs and clinical treatments. 
This topic is a value-driven one and is of interest to the whole society. The participants 
of this study were also asked to consider, which stakeholders should take part in 
evaluating how costs are to influence treatment choices.  
Action research is a diverse approach, as described earlier (Chapter 2.5.). It has several 
features that make it applicable to the present study. Firstly, the present study involves a 
real-life simulation and, quoting Swantz (2011) already repeatedly, “It is crucial that 
research is not separated from life.” Also, as Saaranen-Kauppinen and Puusniekka 
(2006) put it, action research is typically directed in practical issues. One might argue 
that a patient case simulation does not equal real-life situations. Here it is worth noting, 
that the study participants are all practicing medical doctors. Therefore, it is reasonable 
to assume that they instantly understand the situation and context of the patient case 
simulation, as they have ‘been there’. Thus, I am positive that there is no misconception 
of the real-life situation. Also, ‘going real-life’ would require that the participating 
organizations had such software, e.g. such electronic patient records, where the costs 
and clinical effects of all treatment choices would automatically pop up on the 
practitioner’s screen. This is not the way electronic patient records in Finland currently 
function, and therefore this study could not have been performed in a real-life situation. 
A second feature whereby the present study fits in the action research approach is that 
the participants were asked to evaluate their own decision-making as well as address 
their values. Action research has, indeed, proved suitable in studies where reflection on 
professionals’ own work is needed (Winter and Munn-Giddings, 2005), or one is 
encouraged to identify one’s values (McNiff and Whitehead, 2002). 
A third feature of action research of note here is that it is characterized as being 
educational (McNiff and Whitehead, 2002; Waterman et al. 2001, cited by Hughes, 
2011), it is used to raise awareness (Poels et al., 2016) and to induce change (Saaranen-
Kauppinen and Puusniekka, 2006). As data on costs is not a traditional parameter in 
clinical decision-making, as already said, the present study also serves the purpose of 
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raising awareness. Hopefully, it will raise cost-awareness within healthcare not only 
among those participating in this study, but also among readers. It might even initiate a 
change in decision-making practices. 
In addition to the three features of action research given above, I would also like to 
bring forward the nature of action research as described by Brydon-Miller et al. (2003). 
The authors explain the nature of action research as compared to natural sciences: 
Action research challenges the claims of a positivistic view of knowledge 
which holds that in order to be credible, research must remain objective 
and value-free. 
 
The present study addresses a theme that definitely is not value-free: the balance of 
costs and health gain. Therefore, action research is a good fit for this study, as this 
approach appreciates the active formation of the participants own thoughts and values. 
Brydon-Miller et al. (2003) also introduce different traditions of action research and 
summarize them followingly:  
As disparate as these traditions are, what links them is the key question of 
how we go about generating knowledge that is both valid and vital to the 
wellbeing of individuals, communities, and for the promotion of larger-scale 
democratic social change.  
 
The present study addresses a question that operates on all the mentioned levels: 
individuals, communities and a large-scale democratic change. The way how medical 
doctors weigh costs in relation to treatment options is a matter of all these levels. While 
the impact of a doctor’s decision on the individual is evident, let me enlighten the effect 
on the society. Healthcare should, democratically so, be equally available to all. Yet, it 
is known that there is diversity in both the availability of treatments for Finnish citizens 
(National institute for Health and Welfare, 2017) and, also, in processes within 
healthcare (Torkki, 2012). Once a further parameter, costs, enters the moment of clinical 
decision-making, there is a potential for even further diversity. Especially the question 
on which stakeholders should evaluate the relation of costs to treatment options is 
central in our society’s ability to achieve equal healthcare for all. Hopefully this study 
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serves in stimulating general discussion on this now, on the eve of the Finnish national 
social and healthcare reform (Ministry of Finance and Ministry of Social Affairs and 
Health, 2017). 
My own position in this study is myself being a medical doctor alike the participants. I 
believe that this affects the participants in the following way. The request to participate 
was sent via email. I know from my own experience, that medical doctors might not 
always be motivated to answer various requests the email box readily offers. A strong 
influence is on the factor of where the request comes from. For example, based on my 
own experience and talks with colleagues, requests to participate in surveys coming 
from the Finnish Medical Association are generally regarded as worth answering, 
whereas those coming from market research companies might not. The former are 
perceived as useful in, for example, the Medical Association developing services for us, 
the medical profession. Colleagues might feel it important or even a duty to answer 
these surveys. The latter example, surveys by market research companies, might include 
questionnaires on, for example, practices of prescribing drugs and reasons for 
prescription choices. Medical doctors might not always regard these as worth 
answering. Therefore, I would like to think that the request to participate in this study 
coming from a colleague – and also provided with the name of the Finnish Medical 
Society Duodecim – raises a positive attitude. 
 
1.1. Summary of the literature review 
 
To briefly recapitulate, this literature review aimed at introducing costing systems used 
in the field of healthcare as well as the theoretical approach of this thesis. Due to the 
uniqueness of healthcare as an industry - health as a ‘product’ not being comparable to 
for example consumer products - it was necessary to first introduce how health outcomes 
are measured. These outcomes may be clinical or performance indicators. The clinical 
outcomes may be classified as those reported by professionals (clinician-related 
outcomes) or by patients or other persons (patient-related or person-related outcomes). 
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The former are typically more objective and easily quantifiable (e.g. blood pressure 
expressed as mmHg) and the latter more oriented in experience or symptoms (e.g. pain, 
well-being). Performance indicators include outcome and process indicators. As in other 
industries, activity that is not effective equals productivity loss. In healthcare it means, in 
addition, unethical exposure of patients to side-effects of unnecessary treatment. In this 
literature review, the Choosing Wisely initiative by the American Board of Internal 
Medicine was introduced. This campaign, that has grown international, aims at ridding 
healthcare of unnecessary treatments that both are waste and expose patients to 
unnecessary risks.  
For assessing costs, systems either acknowledging or not acknowledging clinical outcome 
were introduced. The former includes cost-effectiveness analysis and cost-utility analysis, 
and the latter includes the traditional costing system, and the more developed activity-
based costing system (ABC) and time-driven activity-based costing system (TDABC). 
Cost-effectiveness and cost-utility analyses have been developed in the field of healthcare 
economics. Cost-effectiveness analysis combines clinical effects of treatment with costs, 
and cost-utility analysis combines health-related quality of life with costs. The latter of 
these two, therefore, is a more holistic approach. The other costing systems, ABC and 
TDABC on their behalf, come from industries other than healthcare. Traditionally, costs 
of for example hospital stay have been evaluated by the number of days spent in hospital. 
This has resulted in erroneous costing evaluations, as different activities performed during 
hospital stay were not allocated to those treatments using them. ABC corrects this 
handicap by addressing activities as cost drivers. TDABC takes it a step further, as it also 
addresses time used on activities and time not spent productively. It helps in identifying 
slack and enables more efficient allocation of resources. As a final part of reviewing 
costing systems, the clinically oriented ones and the industry-derived ones were woven 
together by a chapter providing an example on how TDABC and clinical cost-
effectiveness may be combined, thereby combining two important entities: resource use 
and health gain.  
Action research was introduced as a theoretical approach of this study. It is a versatile 
approach that is strongly connected to practice. It has also been widely used in the context 
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of health care, examples of which were given. Action research may be used to study 
organizational and managerial work practices, or individual work practices, as in this 
study. My own position here is myself being a medical doctor like the participants. 
Hopefully this has raised a positive attitude towards the study among them.  
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3. Methods 
  
The project was carried out in collaboration with Nordic Healthcare Group Ltd., a Finnish 
company specialized in planning and developing health and social services, and with The 
Finnish Medical Society Duodecim, a scientific association established in 1881 to 
develop the professional skills and clinical practice of doctors. The Finnish Medical 
Society Duodecim produces Current Care guidelines. These are independent, evidence-
based clinical practice guidelines made applicable to medical practice in Finland (Current 
Care Guidelines, 2015). 
The study was performed in Finnish. In the following, I will describe composing the 
clinical cases (Chapter 3.1.), present the study questions (Chapter 3.2.), as well as present 
the participating organization and describe how the study was performed (Chapter 3.3.). 
Finally, study ethics is considered (Chapter 3.4.). 
 
3.1. Composing the cases 
 
To provide a real-life simulation, clinical patient cases needed to be constructed. For this, 
the first step was to decide what or which diseases to choose. It was agreed on that the 
following three criteria should be met. 
- The disease(s) should be common and therefore carry a significant disease 
burden nationally. 
- There should be more than one effective treatment option. 
- There should be a Current Care clinical practice guideline available for the 
disease. 
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The first criterion was considered to make the case more interesting and meaningful. It 
would also, depending on the results, offer the possibility of cost reductions as a 
largescale disease burden is addressed. The second criterion is natural, as without an 
option for choice there would be no decision-making. The third criterion is a pragmatic 
one. The benefits and harms (effects and side-effects) of treatments are to be found in 
Current Care guidelines, where medical scientific knowledge is transparently and 
systematically evaluated. The Current Care guidelines also define themselves as covering 
“important issues related to health, medical treatment and disease prevention in Finland” 
(Current Care Guidelines, 2015). Therefore, they cover diseases that carry significant 
national burden and, therefore, the third criterion actually includes criterion one.  
The number of diseases, and therefore the number of patient cases to be constructed for 
the study, was then to be decided. An informal inquiry among Current Care guideline 
editors was done to explore options. The following three diseases were chosen for this 
study: depression of moderate severity, bulimia nervosa and deep venous thrombosis. The 
impact on national disease burden is given as their prevalence in Table 1. 
 
Table 1. Prevalence of the three diseases chosen for the cases. 
 
Disease Prevalence 
Depression of moderate 
severity 
5 % annual prevalence in Finnish adult population (Pirkkola, S.P., 
2000) 1 
10 % estimated prevalence in patients of primary care (Vuorilehto, 
2005) 1 
Bulimia nervosa 0,9-2,3 % in women, 0,1-0,5 % in men, life-time prevalence (Keski-
Rahkonen, 2009; Preti, 2009) 
Deep venous thrombosis 0,1-0,2 % annual prevalence (Silverstezin, 1998) 
1 Includes depression of all severity, not only that of moderate degree 
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For each of the above diseases a fictitious, but typical patient case was constructed. As 
medical doctors are generally busy and occupied with their clinical work, it was seen 
crucial that the patient cases were kept short (Table 5). The cases descriptions were 
accompanied by treatment options, for which the harms and benefits (effects and side-
effects) as well as costs were given. The data on harms and benefits was taken from 
Current Care guidelines (2015). Data on costs were retrieved from databanks in the 
courtesy of NHG Benchmarking Ltd. These costs are based on costs of treatment 
episodes, which are expressed as costs per patient. These are based on time-driven 
activity-based costing (Kaplan and Anderson 2004; Kaplan and Porter, 2011). The cost 
data used in this project derives from real-life costs in Finnish health care. It would be 
based on these data that the participants would be asked to make their treatment choice.  
 
3.2. The study questions  
 
After making their choice of treatment the participants were asked to answer three 
questions. These were: 
1. Did the information on costs affect your clinical decision-making? 
2. Why so? Please read the following claims and choose on the scale from one to 
five whether you agree with the claim or not (one=strongly disagree, five=strongly 
agree). 
3. Whom or which stakeholder, in your opinion, should be involved in evaluating 
how costs are to be considered in clinical decision-making? Please mark on the 
following choices ‘yes’ or ‘no’. 
For question number two separate claims opened for those who answered ‘yes’ to 
question number one and for those who answered ‘no’. For question number three, an 
equal list of choices opened for all, irrespective of the answer for question number one. 
The list of claims for question number two are given in Table 2 and the list of suggestions 
for question number three are given in Table 3.
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Table 2. List of claims in study question number two.  
 
Claims that come visible after having answered ‘no’ to question number 
one1 
Claims that come visible after having answered ‘yes’ to question number 
one1 
i. Treatment decisions should be made on clinical grounds, and costs 
should not affect the decision. 
ii. In a clinical situation, there is no time to think about costs. 
iii. As a doctor treating my patients it is not my job to think about 
costs in the first place. 
iv. It is hard for me to decline a treatment from a person wanting it, 
even though I would know the treatment is not cost-effective. 
v. The information on costs does not affect my decision-making, 
even if I would know that the patient would have to pay a part of 
e.g. medication. 
vi. Bringing information on costs visible is neither interesting nor 
necessary. 
 
i. I take costs into account and discuss them with my patients in 
case the patient should have to pay part of e.g. medicines. 
ii. If treatments are clinically equal (benefits and harms) the 
cheapest option should be taken, especially if the society pays 
for the treatment. 
iii. When society pays the treatment, I think also the cheaper 
option is a choice, even though it would not be clinically 
optimal, especially if the difference in costs is remarkable. 
iv. When society pays the treatment one should always choose the 
most cost-effective choice, as in this way taxpayers’ money 
will be available for as many in need of treatment as possible. 
v. When society pays for the treatment, it is unethical use of tax-
payers money to choose treatments that are not cost-effective. 
vi. It is both welcome and modern to bring information on costs 
visible. 
 
1 Question number one: “Did the information on costs affect your clinical decision-making?” All original questions and claims were in 
Finnish. 
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Table 3. List of suggestions in study question number three on whom or which stakeholder 
should be involved in evaluating how costs are to be considered in clinical decision-
making. 
 
Medical doctor treating patient 
Organizations’ (e.g. hospital’s or healthcare center’s) management 
Health scientists 
Local politicians 
Ministry of Social Affairs and Health / Parliament 
Insurance companies 
The National Advisory Board on Social Welfare and Health Care Ethics (ETENE) 
A model from another western country should be adopted 
Other person or party, who or which? (open space provided) 
 
 
3.3. Participating organizations and performing study 
 
Decisions on which health care units to ask for as collaborators were based on the nature 
of the cases. Deep venous thrombosis is typically treated in emergency rooms of hospitals 
that have 24-hour medical on-call service. Depression of moderate severity is typically 
treated in specialist care within hospitals. Bulimia nervosa is typically treated in primary 
care, including school health care. Basically, any healthcare unit in Finland could have 
been asked. The choice of whom to ask may be described as half-random. The following 
Finnish healthcare units were asked and they kindly agreed. 
- Central Finland Central Hospital, Emergency clinic for case 
Deep venous thrombosis 
- Helsinki University Hospital, Department of Mood 
Disorders for the case of depression of moderate severity 
- City of Turku, Welfare Division for case Bulimia nervosa 
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The study was performed with the Questback Essentials internet-based program. It 
enables a questionnaire which proceeds according to what the respondent answers to each 
question. This feature was needed when proceeding from study question one to question 
two, as described above. The study questionnaire was accessed via a link that the 
participants received by email. 
The research links were first opened for two weeks in two of the three organizations and 
for eight days in one organization. The latter was due to organization-dependent schedules 
that allowed the third organization to start later than the other two organizations. During 
this initial phase, only few answers were obtained from each organization. For the first 
two organizations, the initial e-mail was sent from Nordic Healthcare Group. Due to the 
small response rate one of the organizations themselves suggested that another email 
would be sent from within their organization, as this might promote a better response. 
This practice was then applied for both of those organizations that started first and, also, 
directly applied to the third organization, which now sent its first email. Along with this 
reminder one of the organizations (case Depression) also expanded the email circulation 
within their organization. One further reminder was sent from within two organizations, 
and two further reminders from within one organization. In all, response rates were not 
high, between 13 and 47 per cent. The numbers of responses are given in Table 4. 
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Table 4. Cumulative number of responses obtained following each email sent, given by 
cases. 
 
 Number of responses (number recipients of emails) 
 Depression Deep venous 
thrombosis 
Bulimia 
Initial email sent from Nordic 
Healthcare Group 
 
2 (18) 4 (32) na 
Initial email sent from within 
own organization 
 
na na 6 (86) 
Reminder sent from within 
own organization 
 
17 (200) 11 (32) 11 (86) 
Another reminder sent from 
within own organization 
 
20 (200) 15 (32) na 
A third reminder sent from 
within own organization 
 
30 (200) na na 
Final number of responses 30 (200) 15 (32) 11 (86) 
na = not applicable 
 
3.4. Ethical aspects 
Concerning research ethics, I think this study should apply the general ethical rules when 
involving human subjects, as outlined by Brydon-Miller (2011). These include treating 
study subjects by respectfully, but also by providing a research protocol that is potentially 
beneficial, and definitely not harmful, to them. In addition to the study subjects Brydon-
Miller (2011) also pays attention to the institutions of both the participants and the 
researches themselves. Further, attention is given to fellow researchers and the 
relationships between the principal researcher and peers (Brydon-Miller, 2011). In the 
field of health care and medical research there are further ethical codes of conduct 
provided by the World Medical Association, based on the initial Declaration of Helsinki 
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in 1964, and since revised (World Medical Association, 2013). However, as the present 
project does not involve medical patients or individualized patient data, it is the codes 
outlined by Brydon-Miller (2011) rather than those of the World Medical Association 
(2013) that become emphasized. Concerning studies performed as part of thesis work, 
Helsinki University Hospital and Turku Welfare Division had research permission 
protocols, that were followed (decisions no 9/2017 and 390492, respectively). 
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4. Findings, analysis and discussion 
 
The purpose of this study was to find out whether information on the costs of treatment 
would affect Finnish medical doctors’ clinical decision-making. The rationale behind this 
was the fact that medical doctors are the ones making clinical treatment decisions and, 
therefore, they inherently are in key position on deciding on costs. A larger practical 
implication lies in whether leading doctors by cost information would result in cost 
reductions. On the way there, this study focused on the first step necessary: to find out 
whether medical doctors see information on costs to affect their clinical decision-making 
in the first place, and why so. As this is tied to the discussion on whom or which party 
should be the one(s) making these decisions on the relations of costs and treatments 
offered, the doctors were also asked about this. 
In this chapter, the findings are presented along with their analysis as well as a broader 
discussion. This structure was chosen as it seemed to fit naturally. The analysis and 
discussion are very close to each other, and it is only a fine line where analysis ends and 
a broader discussion begins. Several of the themes discussed below are such that it would 
have felt artificial in splitting the chapters in two parts, for the purpose of structuring 
some thoughts under an upper rubric of ‘analysis’ and some under another upper rubric 
of ‘discussion’. The compact chapter on ethicality is one good example (Chapter 4.8.).  
The reader will be taken through the findings, along with their analysis and discussion, 
by grouping them into ten themes. The themes are based on analysis of the findings, which 
originally include the following five steps or entities in data collection:  
- response rates, 
- answers to the initial study question on whether cost 
information affected clinical decision-making, 
- responses to six different claims in survey question two, 
with these claims being different for those who answered 
‘yes’ and for those who answered ‘no’ to the initial 
question, equaling a total of twelve claims, 
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- answers to the third and final study question on whom or 
which stakeholder should be involved in evaluating how 
costs are to be considered in clinical decision-making, and 
- the literature review, with reference to the costing systems. 
The ten themes introduced below may include findings from one or more of the above 
steps. For example, the chapter on ethicality (Chapter 4.8.) includes findings from only 
one claim in study question number two, whereas the chapter on society as a paying party 
(Chapter 4.7.) includes input from three claims presented in study question number two, 
and the chapter on stakeholders in evaluating how cost information should affect clinical 
decision-making (Chapter 4.9.) includes findings from both study questions two and 
three. This grouping of findings by themes was, thus, done flexibly according to the topic 
rather than by arithmetical order of the study findings. This approach was considered 
more meaningful and, hopefully, also more interesting to the reader.    
Concerning the graphical presentations of the findings, the results are given both by case 
and as a total number. However, once analyzing and discussing the findings total 
numbers, that combine all responses, are used. This is due to the limited number of 
responses by case. Therefore, making conclusions on how colleagues from different 
specialties or organizations see or value the issue on costs, as compared to colleagues 
from other specialties or organizations, would be somewhat far-fetched and might lead to 
over- or misinterpretation. Thus, the total numbers given below are more interesting, and 
give a better ground for analysis and discussion. In addition to these, a more detailed 
presentation on how respondents chose between stakeholders in study question number 
three is given in the appendices (Appendix 3 and 4). 
 
4.1. Response rates  
 
The response rates to this study were rather low, between 13 and 47 per cent. This limits 
the ability to draw conclusions and generalize the results into all Finnish medical doctors. 
However, I do not find this low response rate surprising, and I am grateful to all those 
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colleagues who took their time to answer the questionnaire. Let me consider reasons I 
believe there are behind the low response rate among doctors. I would like to suggest 
three major ones, although more may exist. Firstly, doctors carry a big work burden and 
work days tend to get rather busy. Secondly, alike many other professionals, doctors tend 
to get a lot of information via email, and questionnaires compete in this email load. 
Thirdly, doctors might get various kinds of requests to answer questionnaires, and not all 
might be eager on these. Let me briefly address each of these points separately. 
The work burden of medical doctors often gets heavy. This has been acknowledged across 
nations (Panagioti, et al., 2017). In Finland, the Finnish Medical Association has regularly 
addressed the work environment, work burden and well-being of Finnish medical doctors 
(Kosonen, 2016). I find it understandable that questionnaires or any other tasks that are 
not directly related to one’s work may be ignored. This might not necessarily mean that 
there would be any hostile or negative attitude, but just the workload itself prevents from 
using energy to tasks other than core ones. 
Another reason for not using effort to answering questionnaires might be the information 
load coming via email. As I know from my own experience, medical doctors tend to get 
their own load of emails. These should be tended to on the time spared from clinical work. 
Most of a practitioners’ time is directed to patient work. Even though this includes 
computer work, the computer is not used in the sense that one could, for example, check 
emails, not to speak of answering questionnaires. In clinical work the computer is used 
because of electronic patient records. Therefore, the time for reading emails and reacting 
to them is a limited part of the working day. In this time slot, medical doctors also need 
to react to various work instructions concerning their clinical work, such as new 
instructions on where particular patients should be referred to or which new ways 
particular laboratory tests should be there-on ordered. This type of information might 
easily override other, not so important messages, which might not reach the medical 
doctor’s attention. 
A third notion could be an attitude towards questionnaires. I know that medical doctors 
tend to get requests to participate in various kinds of surveys. These include surveys 
performed by commercial companies and done for marketing purposes. These might not 
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catch the interest of a medical doctor. It is possible that any request to answer a 
questionnaire per se already makes the recipient ignore the request and move on to the 
next email. However, I also believe that the nature of the present study, coming from a 
colleague and including the Finnish Medical Society Duodecim as one partner, might 
have risen a positive perception among recipients. 
Finally, I would like to note that the response rates might also be compared by cases or 
by organizations, which either way expressed. However, I did not find this a sound 
approach as the numbers are too small for statistical comparisons. Yet, I chose to present 
the results by separating cases rather than by giving only total figures. This enlightens the 
slight differences in how the process of initial emails and reminders proceeded by case, 
and might provide ideas for others planning similar studies among Finnish medical 
doctors working within public health care. 
 
4.2. The degree to which information on costs affected decision-making  
 
After reading the patient case the respondents were asked to select from given treatment 
options, the number of which ranged from two to three. For two cases (Depression of 
moderate severity and Bulimia nervosa), all given options were chosen at least once. In 
one case (Deep venous thrombosis) one of the treatment options was not chosen by any 
respondent (Table 5).  
All treatment options are evidence-based choices and are given in the Finnish national 
clinical practice guidelines, the Current Care Guidelines (2015). Thus, all choices are apt 
choices and in the repertoire of clinicians. The reason for one choice being left unchosen 
by any respondent may not be evaluated based by this first question, as it only required a 
yes or no -answer.  
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Table 5. Features of the three patient cases and treatment options in the survey, and distribution of choices between treatment options. 
 
 Length of 
case (words) 
Treatment alternatives given, cost Cost of treatment 
Number of times chosen 
Depression of 
moderate severity 
84 a. Oral medication (citalopram) for eight months 
 
b. Short psychotherapy 
 
c. Combining medical therapy for eight months with short psychotherapy 
 
d. Combing medical therapy for eight months with internet-based therapy 
(e-therapy) 
221 € 
n = 5 
680 € 
n = 4 
721 € 
n = 15 
 
681 € 
n = 6 
Deep venous 
thrombosis 
165 Oral medication for three months, three choices: 
a. Medicin I daily (warfarin)1, upon initiation daily subcutaneous 
injections (enoxaparium) are needed for appr. a week 
 
b. Medicin II twice a day (dabigatran), upon initiation daily subcutaneous 
injections (enoxaparium) are needed for five days 
 
c. Medicin III twice a day, (rivaroxaban) 
 
 
550 € 
n = 0 
 
 
340 € 
n = 2 
 
320 € 
n = 13 
Bulimia nervosa 270 a. Oral medication (fluoxetine) for six to 12 months, doctor’s and nurses’ 
appointments 
 
a. Internet-based therapy (e-therapy, eCBT2) 
 
970 € 
n = 6 
 
640 € 
n = 5 
1 requires approximately 15 blood sample controls during treatment period. 2 CBT = cognitive behavioral therapy 
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After making the treatment choice the respondents were asked to answer the first question 
on whether the information on costs affected their decision-making. This was a yes or no 
-question. More than half, 35 out of 51 (68 %) responded that the information on costs 
did not affect their clinical decision-making, while the rest said it did (Figure 1). Based 
solely on this finding, it could be concluded in a straight forward manner that leading 
doctors by information on treatment costs would be a limited leadership practice – in 
terms of wanting to achieve cost reductions – as one could only reach less than half of 
them. As what comes to the reasons behind this finding, implications are offered in the 
other themes discussed below. 
 
Figure 1. Results on whether the information on costs affected clinical decision-making. 
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4.3. Attitudes towards bringing information on costs visible at the point of care  
 
In this study, most medical doctors did not object to information on costs of treatment 
being made visible. Quite the contrary, this information was welcomed. In the second 
study question, a claim about this was presented for both those answering ‘yes’ and those 
answering ‘no’ to the initial question. Of those having answered ‘yes’ most respondents 
strongly agreed that ‘It is both welcome and modern to bring information on costs visible.’ 
(Figure 2). Of those having answered ‘no’, none strongly agreed with the claim: ‘Bringing 
information on costs visible is neither interesting nor necessary.’ (Figure 3). However, 
while in the ‘yes-group’ responses were rather unanimous (positive towards information 
on costs), in the ‘no-group’ the responses were somewhat more spread out: approximately 
a fifth rated two or three on the scale, indicating either no agreement or disagreement with 
the claim, or agreement to some extent. Still, as a whole, I find it fair to conclude that the 
majority of all respondents seem to have a positive attitude towards making information 
on costs visible at the point of care. I agree with these respondents, and I could even say 
that their answers prove that this thesis has been of a current topic. 
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Figure 2. Responses to claim: ‘It is both welcome and modern to bring information on 
costs visible.’ 
 
Figure 3. Responses to claim: ‘Bringing information on costs visible is neither interesting 
nor necessary.’ 
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4.4. The doctor’s time 
 
It is generally known that medical doctors tend to carry a big work load. Therefore, to 
find out whether time limits would be a determining factor on whether medical doctors 
consider costs at the point of care, the following claim was presented to those answering 
‘no’ to the initial question: ‘In a clinical situation, there is no time to think about costs.’ 
Here the respondents used the whole range of the answering scale, with both the mode 
and median being choice two, i.e. slight disagreement with the claim (Figure 4). It 
therefore seems that most of these respondents did not perceive time to be a limiting factor 
here. Indeed, medical doctors are used to handling more than one aspect of a problem 
(health problem) at a time. Also, medical doctors are used to making decisions within a 
time frame that may be set either by the organization (e.g. appointment schedules), nature 
of work unit (e.g. emergency unit, with a queue of patients requiring attendance) or nature 
of the illness (e.g. brain or myocardial infarct, where a patient’s prognosis depends on the 
tempo of clinical diagnosing and decision-making). Thus, for approximately two thirds 
of the respondents the reasons for leaving costs out of clinical decision-making lie 
elsewhere than in use of time. However, it does not mean that members of the medical 
profession would be immune to the psychological burden of time pressure: 10 out of 35 
respondents (29 %) did agree with the claim. This is in line with the finding by Francke 
et al (2008). The authors report how time might be one factor limiting the implementation 
of new clinical guidelines among doctors.  
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Figure 4. Responses to claim: ‘In a clinical situation, there is no time to think about costs.’ 
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way. A majority, 69 % or the respondents, agreed with the claim. The remaining 31 % 
either placed themselves in the middle or expressed disagreement to some extent. (Figure 
5). I do not find this result surprising as it indeed reflects my profession’s basic principle, 
to work for the best of the patient, and this claim might raise the thought of having to 
make a trade-off between money and health. Also, in clinical treatment decisions, parallel 
treatments may be evaluated against their benefits and harms (effects and side-effects), 
the effort the patient should make, and possible other simultaneous health problems 
(comorbidity). Each of us would, as a patient, have different preferences on which of the 
following, to give a few examples, would be preferable: weekly injections or daily oral 
medication, treatment requiring weekly laboratory visits or treatment with no laboratory 
visits but more side-effects, or a side-effect of headache against diarrhea. Once costs of 
treatment – those to be carried by the patient – are added to the equation, each of us would 
probably evaluate one’s preferences again. These individual values and preferences are 
often seen the standpoint from which treatment decisions should be made, for a person to 
commit to the treatment. This might also relate to the responses given for the claim: ‘It is 
hard for me to decline a treatment from a person wanting it, even though I would know 
the treatment is not cost-effective,’ which was presented to those who answered ‘no’ to 
the initial question. For this claim, the whole scale of answers was used, with the median 
and mode both being two, i.e. somewhat of disagreement with the claim (Figure 6). This 
distribution of responses I find descriptive of the versatile nature of the doctor-patient 
interaction and, also, of the attempt of doctors to find a common ground with their patient. 
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Figure 5. Responses to claim: ‘Treatment decisions should be made on clinical grounds, 
and costs should not affect the decision.’ 
 
Figure 6. Responses to claim: ‘It is hard for me to decline a treatment from a person 
wanting it, even though I would know the treatment is not cost-effective.’ 
 
0 5 10 15 20
1
2
3
4
5
Number of respondents
1
 =
 s
tr
o
n
gl
y 
d
is
ag
re
e.
..
 5
 =
 s
tr
o
n
gl
y 
ag
re
e
Treatment decisions should be made on 
clinical grounds, and costs should not affect 
the decision.
Total Depression Deep venous thrombosis Bulimia nervosa
0 2 4 6 8 10 12 14 16 18
1
2
3
4
5
Number of respondents
1
 =
 s
tr
o
n
gl
y 
d
is
ag
re
e.
..
 5
 =
 s
tr
o
n
gl
y 
ag
re
e
It is hard for me to decline a treatment 
from a person wanting it, even though I 
would know the treatment is not cost-
effective.
Total Depression Deep venous thrombosis Bulimia nervosa
 53 
 
 
Another factor, and a highly traditional one in the art of medicine, that could limit the 
potential to lead doctors by cost information, is the spirit of the Hippocratic Oath. A 
doctor should act to the best of one’s patient. At the level of individual patients, one would 
only need to think about benefits and harms of treatment, and efforts and costs falling to 
the patient, as discussed above. Costs falling to the organization or society would not be 
in key focus. However, if we have limited resources in our society to spend on healthcare, 
could treating one patient mean leaving another one untreated? We have, in our Finnish 
national debate, been challenged to think about this issue (Kekomäki, 2016). 
 
4.6. The patient and citizen as a paying party  
 
Even though public health care in Finland is available for all citizens free or at a very low 
cost, citizens would typically pay a part of their medicines themselves. To find out how 
medical doctors would consider these costs falling directly to the patient in their clinical 
decision-making, the following claims were presented. Those who had answered ‘yes’ to 
the initial question were given the claim: ‘I take costs into account and discuss them with 
my patients in case the patient should have to pay part of e.g. medicines.’ Most 
respondents agreed (Figure 7). Those who had answered ‘no’ to the initial question were 
given the claim ‘The information on costs does not affect my decision-making, even if I 
knew that the patient would have to pay a part of e.g. medicines.’ Here, no respondent 
strongly agreed with the claim, and the median and mode were two, i.e. somewhat 
disagreement with the claim (Figure 8). It seems, thus, that irrespective of whether the 
respondent answered ‘yes’ or ‘no’ to the initial question on whether information on costs 
affected the respondent’s clinical treatment decision, the respondent would still address 
costs with the patient, in case these costs would fall for the patient to carry. 
I think this practice is, firstly, good customer service and, secondly, leads to better 
compliance with treatment. If, for example, a patient would consider the medical drugs 
too expensive, this could lead to either of the following: a) the drugs not being purchased 
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at all, and hence no treatment started, b) the drug being purchased but not used according 
to instructions (e.g. with a smaller dose or more seldom than recommended), or c) 
treatment being delayed due to patient returning to the doctor to ask for cheaper drugs. 
These outcomes would either lead to a) no health effect, b) reduced health effect, or c) 
delayed health effect. As health effect is the output of the doctor’s appointment and of the 
health industry in general, then all the mentioned outcomes should be avoided. Based on 
the answers by the respondents, it may be concluded that Finnish medical doctors are well 
aware that costs of treatment, e.g. medical drugs, when carried out by the patient him- or 
herself, affect treatment compliance. Further, medical doctors wisely take this into 
consideration at the appointment. 
 
Figure 7. Responses to claim: ‘I take costs into account and discuss them with my patients 
in case the patient should have to pay part of e.g. medicines.’ 
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Figure 8. Responses to claim: ‘The information on costs does not affect my decision-
making, even if I knew that the patient would have to pay a part of e.g. medicines.’ 
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was left fully reimbursed while other diabetes medicines lost their status of full 
reimbursement. Since January 1st, 2017 these other medicines have only been reimbursed 
by 65 % for the part that exceeds the initial deductible of 50 euros. This change of 
reimbursement practice will affect slightly more than 300 000 persons.  This is an 
example of effectively reducing society’s health care costs by regulations that do not 
affect doctors. Firstly, this shows that reductions in society’s medicine costs do not only 
derive from what a doctor prescribes. Thus, I hereby partly contradict my initial statement 
in this thesis, where I cited the old saying that ‘the doctor’s pen’ determines most costs 
in healthcare. Secondly, this shows that the concept of leading doctors by cost information 
would not always even be needed for achieving societal cost reductions within health 
care. 
 
4.7. The society as a paying party  
 
Three claims were particularly aimed at considering the role of the society as a paying 
party. These were presented to those respondents who answered ‘yes’ to the initial 
question on whether cost information affected the respondent’s clinical decision-making. 
The first of these claims was: ‘If treatments are clinically equal (benefits and harms) the 
cheapest option should be taken, especially if the society pays for the treatment.’ Most 
respondents agreed with the claim, although now also number two from the five-step scale 
was used, indicating disagreement to some extent (Figure 9). In this claim the benefits 
and harms of treatment options were assumed equal, i.e. the claim was set to be neutral 
in health gain. However, I would not have been surprised even if all respondents had 
chosen ‘5’ on the scale, to strongly agree with the claim, as in this way society’s money 
could be saved. However, as the respondents used the spectrum from two to five, I assume 
colleagues also considered other factors than those given in the claim. These could 
involve factors such as differences in treatment protocols (invasive vs. non-invasive 
treatment, differences in dosage or delivery route of medication, frequency of laboratory 
visits), which might affect which treatments patients prefer. Due to these kinds of factors, 
some might be more compliant to treatment protocols that are not the cheapest choices. 
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Figure 9. Responses to claim: ‘If treatments are clinically equal (benefits and harms) the 
cheapest option should be taken, especially if society pays for the treatment.’ 
 
 
 
The next claim, and second in row addressing the society, was a continuation of the 
thought in the previous one: ‘When society pays the treatment, I think also the cheaper 
option is a choice, even though it would not be clinically optimal, especially if the 
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Figure 10. Responses to claim: ‘When society pays for the treatment, I think also the 
cheaper option is a choice, even though it would not be clinically optimal, especially if 
the difference in costs is remarkable.’ 
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wisely by using the most cost-effective choice. Alike in the above claim assuming equal 
health gain (Figure 9), the spectrum of agreement spanned from slight disagreement to 
strong agreement, with the emphasis being on agreement (Figure 11). This is different 
from the span of responses to the claim assuming unequal health gain (Figure 10), 
where the distribution of responses spread more evenly between agreement and 
disagreement with the claim. These responses might reflect the general notion that for 
us doctors it is always easiest to choose, and we are typically more unanimous, if a 
treatment is clinically effective and health gain need not be compromised. 
 
Figure 11. Responses to claim: ‘When society pays the treatment one should always 
choose the most cost-effective choice, as in this way taxpayers’ money will be available 
for as many in need of treatment as possible.’ 
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4.8. Ethicality  
 
Ethicality is a theme that may not be left unnoticed when talking about healthcare. In one 
claim, ethicality was actively mentioned. It was presented to the group that answered 
‘yes’ to the initial question on whether cost information affected their clinical decision-
making: 'When society pays for the treatment, it is unethical use of tax-payers' money to 
choose treatments that are not cost-effective.’ This claim was the first that showed a 
polarized distribution of responses, even though it was only one respondent who chose to 
strongly disagree with the claim. Almost all others agreed, as only one respondent chose 
option three in the middle (Figure 12). Thus, the responses were more unanimous than 
those for the earlier claim: ‘When society pays the treatment one should always choose 
the most cost-effective choice, as in this way taxpayers’ money will be available for as 
many in need of treatment as possible.’ (Figure 11). This I find interesting as this earlier 
claim, also naming taxpayers as the paying party, already comes close to ethicality.  
Cost-effectiveness is a concept familiar to medical doctors. In a way, it is a neutral term, 
as it only addresses the input of resources in relation to health out-put. Therefore, it does 
not as such contradict with ethical issues. Interestingly, the responses by medical doctors 
participating in this study were somewhat more heterogenous when asked about should 
the most cost-effective treatment choice always be taken when society pays for the 
treatment, for tax payers’ money to be available for as many as possible. This theme might 
provoke a wider range of views, as it holds the idea of having to think of other persons’ 
interests when treating one individual. Also, a treatment that is less cost-effective than 
another one may still be effective in clinical terms. As Saarni, in his doctoral thesis 
‘Effectiveness in Health Care Decision-making. An Ethical Analysis’ (Saarni, 2010) 
points out, cutting out treatments that are even a little effective, would be regulating, 
whereas cutting out treatments that are not effective, would not. Decisions on regulating 
and prioritizing are usually perceived difficult due their ethical involvement, which is one 
reason why there tends to be various opinions.  
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Figure 12. Responses to claim: 'When society pays for the treatment, it is unethical use of 
tax-payers' money to choose treatments that are not cost-effective’ 
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disagreed and, therefore, it can be concluded that they might see a medical doctor 
considering costs along with clinical aspects. To me this interpretation – naturally, 
interested in the topic as I am – sounds welcome. However, the results presented in Figure 
13 should be analyzed keeping in mind that these respondents answered ‘no’ to the initial 
question on whether information on costs affected their clinical decision-making in the 
firsts place. At first thought, it might be seen contradictory to answer ‘no’ to the initial 
question and then not to agree with this claim. However, these two are not in contradiction 
with each other. Detaching information on costs from the point of making clinical 
treatment decisions does not exclude that practicing doctors could not, or would not think 
that they should, take part in considerations on costs. The implication that could be drawn 
here is that these considerations on costs should be done at a time other than that of the 
doctor-patient interaction. 
 
Figure 13. Responses to claim: ‘As a doctor treating patients it is not my job to think 
about costs in the first place.’ 
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Proceeding now to the moment other than that of the patient interaction, let us consider 
the third and final question of this study. It addressed the topic of whose role it is to 
evaluate the impact of costs on treatment decisions. Respondents were given eight choices 
ready, and an open space was left for further suggestions. Respondents were free to 
choose as many options as they wanted. A total of 158 choices were made by the 56 
respondents. Approximately half of the respondents, 27 out of 56 (48 %), chose only one 
or two options. The other half chose three options or more (Figure 14). 
 
Figure 14. Information on how many options of different stakeholders were chosen by 
one respondent.  
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Most respondents, 46 out of 56 (82 %), saw that the medical doctor treating patients 
should be involved in evaluating how costs of treatments are to be evaluated in clinical 
decision-making (Figure 15). Of them, most (29 out 46) also chose the health care 
organization’s management (Appendix 3). Organizational management was chosen 36 
times in total (64 % of respondents). Of the minority of ten respondents who did not 
choose the medical doctor, seven chose the local organizational management and six 
chose the Ministry of Social Affairs and Health or the parliament as a stakeholder 
(Appendix 4). 
 
Figure 15. Opinions on whom or which stakeholder should be involved in evaluating how 
costs are to be considered in clinical decision-making. 
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costs on the local level. Of interest is to note that at present, most managerial positions in 
public sector health care organizations are held by medical doctors. It would be interesting 
to see whether medical doctors would still value the local management as a stakeholder 
in case these positions would substantially fall outside the profession of medical doctors 
and other healthcare professionals to others, such as professionals in business 
administration and other economic sciences, or industrial engineering and management. 
Political institutions and policy makers form one stakeholder. Half of the respondents 
chose the Ministry of Social Affairs and Health or the parliament as a stakeholder (Figure 
15). Of these 28 respondents, most had also chosen the medical doctor (22 out of 28) and 
the local organizational management (21 out of 28; Appendix 3). Local politicians, 
however, were not often voted for. It might be, that the reason for these respondents 
choosing the Ministry as a stakeholder that should carry the responsibility of evaluating 
how costs are to affect availability of clinical treatments, lies in the Ministry being an 
organ with the possibility to implement social and health policy on all parties acting in 
health care. 
The National Advisory Board on Social Welfare and Health Care Ethics (ETENE) was 
chosen by approximately a third of the respondents (19 out of 56). I would not have been 
surprised if ETENE would have been recognized even more often, as it is an established 
stakeholder in the Finnish health care field. Further, in case we would have to start 
choosing for example treatments that are not clinically superior but are cheaper, this 
surely holds numerous ethical considerations. 
Players at the national level, like the Ministry and ETENE, have the possibility of 
implementing and guiding equal treatment choices for all citizens, irrespective of for 
example place of residence. This equality could be compromised if all health care 
produces could independently, at the local level, decide on treatments to be offered. This 
thought I base on the findings of Torkki (Torkki, 2012) who, in his doctoral thesis, 
showed that the productivity of different surgical units in Finland is not uniform, and not 
explainable by clinical features of patients or populations. Differences in processes 
offered as an explanatory factor. Therefore, I am not confident that in case all health care 
producers could locally decide on how costs of treatment were to affect treatment choices, 
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that this would result in an equal selection for all citizens. Equality, a generally accepted 
principle in our society, is also written down in how the Ministry of Social Affairs and 
Health defines its role and, also, how the national Current Care Guidelines for clinical 
practice see their role. These are, respectively, “to ensure that everyone has an equal 
opportunity to lead a healthy and socially secure life” (The Ministry of Social affairs and 
Health, 2017) and “to improve the quality of care and decrease inconsistencies between 
treatment practices” (Current Care Guidelines, 2015). Having now touched the topic of 
equality I find it both proper and necessary, for the sake of clarity, to point out that in the 
present study the respondents were offered, in their fictitious patient cases, only such 
treatment options that were derived from the national evidence-based Current Care 
guidelines. Therefore, the respondents answered the study in this context and no other. It 
follows, that even if the respondents mostly chose the local level, medical doctor and 
organizational management, as the parties relevant for deciding on how costs are to be 
accounted for in clinical decision-making, a conclusion may not be drawn that these 
respondents would be promoting either nationally unequal practices or inequality between 
citizens. Such a conclusion would neither be righteous towards the respondents nor based 
on the findings of this study. Rather, my discussion above is an extension of thought 
arising from the topic of this study. 
Another result I find interesting was that health scientists were recognized only by 
approximately a fifth of respondents (13 out of 56), as health science provides means of 
evaluating and comparing clinically meaningful interventions against costs. However, I 
do understand that showing cost-effectiveness or cost-utilities of comparable treatment 
choices does not yet include all the values and preferences a society might have for these 
treatments.  
Only few respondents chose insurance companies or a model from another western 
country to be applied. This could be seen as wanting to detach the financial interests 
insurance companies have, and also recognizing that these issues need to be handled 
domestically, in the Finnish socio-cultural environment. 
The opportunity to use the open space was used only three times. These suggestions 
included the following parties: 
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- the patient 
- National Current Care guideline office 
- The Finnish Medical Society Duodecim and its Current 
Care guideline office, working together with pharmacists 
About political parties it was said that: 
- political decision-making should be clearly separate, 
- political instances might make alignments, but should not 
set restrictions. 
Concerning the small number of free responses, I would assume it is easier to choose 
from options that are set ready, and free writing may be experienced too time consuming. 
Therefore, I would be hesitant to draw a conclusion that all other 53 respondents would 
not come to think of additional parties, were they provided more time or were they 
involved in discussion on the topic. It might also be that if one the options mentioned in 
the free space, for example the national Current Care guideline office, would have been 
given as a ready-set option, it might have been chosen by the respondents. However, as 
this now remains a speculation, let me comment on the suggestions given. The national 
Current Care guideline office has, indeed, occasionally been approached with suggestions 
that it should evaluate the costs of treatments as it produces clinical practice guidelines 
(Komulainen, 2017). Concerning the opinion that political decision-making should be 
clearly separate, I believe there would be others thinking alike in the medical profession. 
What comes to involving patients as stakeholders, I assume the involvement would 
depend on whether the decision-making concerns situations as described in study 
question number two – patient deciding on his or her individual treatments (Figure 7, 
Figure 8) – or whether we think of a general discussion. In the latter case, patient 
organizations, presenting a broader voice, offer as one stakeholder. 
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4.10. Medical doctors and costing systems: a possibility 
 
In addition to national level reimbursements for medicine expenses discussed earlier 
(Chapter 4.6.), there are also other ways to achieve cost reductions in a manner that does 
not involve the practicing medical doctors’ clinical decision-making. Let me consider 
these next, while remembering that it is not, by any means, my intention to lead the reader 
into thinking that the role of the practicing medical doctor as a party affecting healthcare 
costs could be nullified. Moving from the national level to the organizational level, cost 
reductions may be achieved by improving organizational efficiency. This would include 
identifying waste within the organization’s own work practices, and knowing what the 
economic impact of each activity is. Costing methods, introduced in the literature review 
of this thesis, offer tools to manage these. Using them successfully within healthcare 
organizations requires knowledge of the branch and understanding the relationships of 
different activities and professional groups within healthcare organizations. Applying 
these costing methods within healthcare is still relatively new, but a strong need might 
arise once the health, social services and regional government reform planned in Finland 
takes place (Ministry of Finance and Ministry of Social Affairs and Health, 2017). 
According to the plans, public sector health care producers should undergo incorporation 
in the hope of more cost-effective practices. This offers the medical doctors in managerial 
positions a possibility to learn contemporary ways of assessing costs. Then, if financial 
measures would have s stronger foothold in evaluating organizational efficiency, cost 
information might naturally become a means of leading doctors in their practice. 
 
4.11. Summary of findings 
 
For the possibility of seeing the key findings of this study at a glance, these are 
summarized in Table 6. The summary is given according to the themes above. As a 
summary like this is always a simplification of the findings, analysis and discussion, the 
reader is referred to the above chapters for further insight. 
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Table 6. Summary of key findings. 
Theme Key finding, analysis and discussion 
1. Response rates  
 Response rates to the study were between 13 and 47 % in the three 
organizations. Medical doctors are not keen on answering 
questionnaires amidst their clinical work. 
2. Effect on cost information on clinical decision-making 
 For two out of three, the information did not affect clinical decision-
making. 
3. Attitudes towards bringing information on costs visible at the point of care 
 Almost all agreed that this information was welcome. This shows the 
present study was of a current topic. 
4. Time  
 Medical doctors do not see that time would be a limiting or 
determining factor in whether they take costs into account in clinical 
decision-making. 
5. Clinical aspects  
 Medical doctors emphasize clinical aspects, even if they would 
consider costs. 
6. The patient as a paying party 
 Medical doctors would discuss with their patients such costs that fall 
on the patient to carry. 
7. The society as a paying party 
 Medical doctors would choose the cheapest treatment in case the 
options would be clinically equal. In cases of remarkable difference 
in costs, many could choose a clinically inferior treatment. In terms 
of cost-effectiveness, the most cost-effective treatment might 
usually, but not always, be chosen. 
8. Ethicality  
 Medical doctors were relatively unanimous on choosing the most 
cost-effective treatment when considering that tax-payers’ money 
should be made available for as many as possible. 
9. Stakeholders evaluating how information on costs should be taken into 
account in clinical decision-making 
 Most named the medical doctor and local management. A half 
named the Ministry of Social Affairs and Health or the parliament. 
The National Advisory Board on Social Welfare and Health Care 
Ethics (ETENE) was chosen by approximately a third. 
10. Costing systems  
 Several costing methods offer medical doctors the possibility of 
learning contemporary costing assessment. This might come in need 
once the big health, social services and regional government reform 
takes place.  
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5. Conclusion 
 
5.1. Research summary 
 
This thesis was carried out in our times of rising health care expenditure. In Finland in 
2014, health care costs formed 9,5 % of the gross national product, being 19,5 billion in 
euros, and making 3 576 euros per capita (Matveinen and Knape, 2016). Medical doctors, 
as the ones deciding on treatments, hold a key position in defining healthcare expenses. 
With a big health, social services and regional government reform just about to be 
performed in Finland (Ministry of Finance and Ministry of Social Affairs and Health, 
2017), the issue of costs is highly current to medical doctors. 
The point where all medical doctors come across costs of treatment is the everyday point 
of making clinical treatment decisions. In this way, in their patient interaction all 
practicing medical doctors have an impact on healthcare expenditure, whether they 
actively acknowledge it, or want to think about it that way or not. A leadership question 
is whether doctors could be led by information, namely by information on costs. For this 
purpose, the first step necessary was to find out whether medical doctors see information 
on costs to affect their clinical decision-making in the first place, and why so. This study 
was undertaken to take this first step as, to my knowledge, no such study among Finnish 
medical doctors has been performed before.  
The specific research questions were as follows.  
- Does information on the costs of treatment affect clinical decision-making of 
Finnish medical doctors, as evaluated by themselves? 
- What are the reasons that the information on costs does or does not affect clinical 
decision-making? 
- Whom should it be, as evaluated by the doctors, to make decisions on how costs 
of treatment should affect treatment choices? 
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A study was designed with a questionnaire-link sent by email to Finnish medical doctors 
in three different organizations in different geographical locations. After anonymous 
handling of data, it was seen that Finnish medical doctors welcome the information on 
treatment costs alongside clinical information, i.e. the benefits and harms (effects and 
side-effects) of treatment. However, more than half said this information did not affect 
their clinical decision-making. Thus, this information per se does not yet provide a means 
for management in leading medical doctors towards cost reductions. However, doctors 
did take notion of costs falling on the patients. Therefore, medical doctors seem to 
consider treatment options from the patient’s view in a holistic manner: clinical effects, 
costs, and – most likely also, although not asked for in this study – other effort the 
treatment would cause the patient. This is in line with the mentality of the medical 
profession, which derives from the Hippocratic Oath: Primium est non nocere (latin). 
That is, do not harm your patient. We doctors have often taken this to the measures of 
doing everything possible, even though the gain in health and quality of life with maximal 
extra interventions might be marginal. In a scenario where all doctors would continue in 
this manner along with the ever-developing possibilities of diagnostic and treatment 
options, healthcare expenditure would nothing but keep on increasing.  
The respondents were asked about whom or which stakeholder should be involved in 
evaluating how costs are taken into account in clinical decision-making. Most doctors 
thought these evaluations should be kept within the medical profession and at the local 
level. The medical doctor him- or herself was the person or stakeholder most often 
chosen. Also, the healthcare organization’s management was a popular choice. Of other 
stakeholders, the Ministry of Social Affairs and Health gained some support, as did the 
National Advisory Board on Social Welfare and Health Care (ETENE). The stakeholders 
least often chosen were local politicians, insurance companies, or a model from another 
western country. Also, an active suggestion was to involve costs in Finnish national 
clinical guidelines, the Current Care guidelines (2015). These are independent, evidence-
based guidelines that have their own, established status as an information source among 
Finnish healthcare professionals. As a conclusion from these responses, I see them in line 
with the professional autonomy of medical doctors, who are used to drawing their own 
conclusions from information provided. This line of thought would offer leading by 
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information as a means for managing doctors. However, as this study showed, 
information on costs of parallel treatment options is not an efficient way. An opportunity 
might rise in organizational costs, for which costing systems applicable to healthcare were 
reviewed in this thesis. These should be of interest to the profession of medical doctors 
who, in my opinion, should stay in decisive roles once new corporations are formed and 
their cost structures defined in the becoming healthcare reform (Ministry of Finance and 
Ministry of Social Affairs and Health, 2017).  
 
5.2. Practical implications  
 
This study has the following practical implications. Firstly, I hope it will serve as a source 
and stimulator of ideas for managers when considering how medical doctors, as a 
personnel resource, may be led towards cost reducing practices. These ideas might rise 
from not only the direct results obtained in this study but also from the literature review 
and ideas brought up in the discussion. These include: 
a. The point of clinical decision-making might offer limited possibilities for 
cost reductions, as factors other than costs affect the choice of treatment 
more than costs do. 
b. Medical doctors in the public sector, even in managerial positions, might 
not all be fully aware of different costing systems developed and useful 
also in the healthcare industry. A need for this awareness increases along 
with the planned incorporation of public sector health care providers, as 
the health, social services and regional government reform in Finland soon 
takes place (Ministry of Finance and Ministry of Social Affairs and Health, 
2017). 
c. Medical doctors should be actively involved in these future changes, as 
they have profound knowledge of the branch and are central players in 
delivering health care. 
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Secondly, I hope this study will serve as one stimulator to the general discussion on costs 
in healthcare. In this, I see at least the following two entities: 
a. When choices on possible trade-offs between health gain and costs have 
to be made, a broad discussion is needed in the Finnish society. No one 
profession should make such decisions, as the viewpoints are more 
numerous than any one profession holds. Further, no one profession 
should be left with the burden of – or be allowed to – making decisions 
that would practically be choices on prioritizing and regulating patient 
care.  
b. Not all questions of cost reduction and effective practices in health care 
are matters of prioritizing or regulating patient care. In the Finnish public-
sector healthcare there most likely is slack that may be gotten rid of with 
better cost awareness and knowledge of cost-reducing tools. Therefore, 
general discussion on the topic hopefully raises interest and inspires a 
learning spark for cost issues among my colleagues in the medical 
profession.   
 
5.3. Limitations of the study 
 
This study has the following limitations. Firstly, as this study was an initial one among 
Finnish medical doctors’ attitudes towards information on costs of treatment, it does not 
show any evidence of using this information in managing doctors as a personnel resource. 
While it does give ideas for this, conclusions made would remain a speculation.  
As what comes to the conclusions that may be directly drawn, i.e. the direct results of the 
medical doctors’ opinions, it should be kept in mind that this study only reached a small 
part of Finnish doctors. Therefore, the results may not be extrapolated to all Finnish 
doctors even though, intuitively, I would assume many results – like a doctor acting with 
emphasis on clinical issues and not costs – would apply. 
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5.4. Suggestions for further research 
 
The present study was a relatively small one on a highly current topic: Finnish medical 
doctors’ attitudes and opinions on costs of medical treatment options. For further 
research, I would like to make the following suggestions: 
a. The same topic as studied now could be taken wider. A larger study 
among all Finnish colleagues would offer us wider grounds for 
making conclusions alike the ones in this study, as well as for 
producing information that management could better lean on. As a 
party for performing such profession-wide studies I see the Finnish 
Medical Association most suitable.  
b. Further research could go beyond the theme of the present study, 
which was costs of individual treatments. For example, medical 
doctor’s knowledge of costing systems within healthcare could be 
studied. Alike in the present study, this could be accompanied with 
finding out about doctors’ views on whose job it is to handle costing 
issues. This would make a further step on the way of implementing 
cost-knowledge and cost-reducing thinking among medical doctors. 
Also, it would offer insight on how, or by which profession, these 
issues should be managed.  
c. Once the planned health, social services and regional government 
reform in Finland takes place (Ministry of Finance and Ministry of 
Social Affairs and Health, 2017), a huge arena for organizational 
research opens. This reform will be of huge magnitude within the 
healthcare sector. It will not only affect one profession and one topic 
– medical doctors and costs, like in this study – but will affect all 
professionals in the field and will cover changes in work practices, 
human relations and organizational processes, to mention a few. 
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Appendices 
 
Appendix 1. Hippocratic Oath: Classical Version 
 
I swear by Apollo Physician and Asclepius and Hygieia and Panaceia and all the gods 
and goddesses, making them my witnesses, that I will fulfill according to my ability and 
judgment this oath and this covenant: 
To hold him who has taught me this art as equal to my parents and to live my life in 
partnership with him, and if he is in need of money to give him a share of mine, and to 
regard his offspring as equal to my brothers in male lineage and to teach them this art—
if they desire to learn it—without fee and covenant; to give a share of precepts and oral 
instruction and all the other learning to my sons and to the sons of him who has instructed 
me and to pupils who have signed the covenant and have taken an oath according to the 
medical law, but no one else. 
I will apply dietetic measures for the benefit of the sick according to my ability and 
judgment; I will keep them from harm and injustice. 
I will neither give a deadly drug to anybody who asked for it, nor will I make a suggestion 
to this effect. Similarly I will not give to a woman an abortive remedy. In purity and 
holiness I will guard my life and my art. 
I will not use the knife, not even on sufferers from stone, but will withdraw in favor of 
such men as are engaged in this work. 
Whatever houses I may visit, I will come for the benefit of the sick, remaining free of all 
intentional injustice, of all mischief and in particular of sexual relations with both female 
and male persons, be they free or slaves. 
What I may see or hear in the course of the treatment or even outside of the treatment in 
regard to the life of men, which on no account one must spread abroad, I will keep to 
myself, holding such things shameful to be spoken about. 
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If I fulfill this oath and do not violate it, may it be granted to me to enjoy life and art, 
being honored with fame among all men for all time to come; if I transgress it and swear 
falsely, may the opposite of all this be my lot. 
—Translation from the Greek by Ludwig Edelstein. From The Hippocratic Oath: Text, 
Translation, and Interpretation, by Ludwig Edelstein. Baltimore: Johns Hopkins Press, 
1943. 
http://www.pbs.org/wgbh/nova/body/hippocratic-oath-today.html (cited on March 9, 
2017) 
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Appendix 2. Lääkärinvala (in Finnish) 
 
Lääkärinvalassa lääkäri sitoutuu noudattamaan lääkärin eettisiä sääntöjä. Vala 
pohjautuu Hippokrateen valaan sekä Maailman lääkäriliiton vuonna 1949 hyväksyttyyn 
Geneven julistukseen. Lääketieteen lisensiaatit vannovat valan 
valmistumistilaisuudessa.  
https://www.laakariliitto.fi/liitto/etiikka/laakarinvala/ 
Vakuutan kunniani ja omantuntoni kautta pyrkiväni lääkärintoimessani palvelemaan 
lähimmäisiäni ihmisyyttä ja elämää kunnioittaen. Päämääränäni on terveyden 
ylläpitäminen ja edistäminen, sairauksien ehkäiseminen sekä sairaiden parantaminen ja 
heidän kärsimystensä lievittäminen. 
Työssäni noudatan lääkärin etiikkaa ja käytän vain lääketieteellisen tutkimustiedon tai 
kokemuksen hyödyllisiksi osoittamia menetelmiä. Tutkimuksia ja hoitoja suositellessani 
otan tasapuolisesti huomioon niistä potilaalle koituvan hyödyn ja mahdolliset haitat. 
Pidän jatkuvasti yllä korkeaa ammattitaitoani ja arvioin työni laatua. 
Suhtaudun kollegoihini kunnioittavasti ja annan heille apuani, kun he potilaita 
hoitaessaan sitä pyytävät. Rohkaisen potilaitani kysymään tarvittaessa myös toisen 
lääkärin mielipidettä. 
Kunnioitan potilaani tahtoa. Pidän salassa luottamukselliset tiedot, jotka minulle on 
potilaita hoitaessani uskottu. Täytän lääkärin velvollisuuteni jokaista kohtaan ketään 
syrjimättä enkä uhkauksestakaan käytä lääkärintaitoani ammattietiikkani vastaisesti. 
Accessed March 12, 2017 
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Appendix 3. Results on study question 3 “Whom or which stakeholder should be involved in evaluating how costs are taken into account in 
clinical decision-making”. Options chosen simultaneously. 
 
The table shows which options were chosen simultaneously by the respondents. For example, of those 46 choosing ‘Medical doctor treating patient’, 
29 chose ‘Organizations’ (e.g. hospital’s or healthcare center’s) management’ and 16 chose ‘The National Advisory Board on Social Welfare and 
Health Care Ethics (ETENE)’.  
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Appendix 4. Appendix 3. Results on study question 3 “Whom or which stakeholder should be involved in evaluating how costs are taken into 
account in clinical decision-making”. Options not chosen simultaneously. 
 
The table shows which options were not chosen simultaneously by the respondents. For example, of those ten respondents who did not choose 
‘Medical doctor treating patient’, 7 chose ‘Organizations’ (e.g. hospital’s or healthcare center’s) management’ and 6 chose ‘Ministry of Social 
Affairs and Health / Parliament’.  
 
 
 
